<PAPER><mode2 name='PMC3849429' hasDoc='yes' version='597'></mode2><article xml:lang='en' xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>BMC Med</journal-id><journal-id journal-id-type='iso-abbrev'>BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type='epub'>1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>3849429</article-id><article-id pub-id-type='publisher-id'>1741-7015-11-212</article-id><article-id pub-id-type='pmid'>24070457</article-id><article-id pub-id-type='doi'>10.1186/1741-7015-11-212</article-id><article-categories><subj-group subj-group-type='heading'><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1><CoreSc2 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc2>Hypnotics and mortality in an elderly general population: a 12-year prospective study</s></article-title></title-group><contrib-group><contrib contrib-type='author' id='A1'><name><surname>Jaussent</surname><given-names>Isabelle</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>isabelle.jaussent@inserm.fr</email></contrib><contrib contrib-type='author' id='A2'><name><surname>Ancelin</surname><given-names>Marie-Laure</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>marie-laure.ancelin@inserm.fr</email></contrib><contrib contrib-type='author' id='A3'><name><surname>Berr</surname><given-names>Claudine</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>claudine.berr@inserm.fr</email></contrib><contrib contrib-type='author' id='A4'><name><surname>Pérès</surname><given-names>Karine</given-names></name><xref rid='I3' ref-type='aff'>3</xref><xref rid='I4' ref-type='aff'>4</xref><email>Karine.Peres@isped.u-bordeaux2.fr</email></contrib><contrib contrib-type='author' id='A5'><name><surname>Scali</surname><given-names>Jacqueline</given-names></name><xref rid='I1' ref-type='aff'>1</xref><email>Jacqueline.scali@inserm.fr</email></contrib><contrib contrib-type='author' id='A6'><name><surname>Besset</surname><given-names>Alain</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><email>Alain.besset@inserm.fr</email></contrib><contrib contrib-type='author' id='A7'><name><surname>Ritchie</surname><given-names>Karen</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><xref rid='I5' ref-type='aff'>5</xref><email>Karen.ritchie@inserm.fr</email></contrib><contrib contrib-type='author' corresp='yes' id='A8'><name><surname>Dauvilliers</surname><given-names>Yves</given-names></name><xref rid='I1' ref-type='aff'>1</xref><xref rid='I2' ref-type='aff'>2</xref><xref rid='I6' ref-type='aff'>6</xref><xref rid='I7' ref-type='aff'>7</xref><email>ydauvilliers@yahoo.fr</email></contrib></contrib-group><aff id='I1'><label>1</label>Inserm, U1061, Montpellier F-34000, France</aff><aff id='I2'><label>2</label>Université Montpellier 1, Montpellier F-34000, France</aff><aff id='I3'><label>3</label>Inserm, Centre Inserm U897, Bordeaux F-33000, France</aff><aff id='I4'><label>4</label>ISPED, Centre Inserm U897, Université Bordeaux, Bordeaux F-33000, France</aff><aff id='I5'><label>5</label>Faculty of Medicine, Imperial College, London, UK</aff><aff id='I6'><label>6</label>CHU Montpellier, Service de Neurologie, Unité des Troubles du Sommeil, Hôpital Gui-de-Chauliac, Montpellier, France</aff><aff id='I7'><label>7</label>Service de Neurologie, Hôpital Gui-de-Chauliac, 80 avenue Augustin Fliche, Montpellier cedex 5 34295, France</aff><pub-date pub-type='collection'><year>2013</year></pub-date><pub-date pub-type='epub'><day>26</day><month>9</month><year>2013</year></pub-date><volume>11</volume><fpage>212</fpage><lpage>212</lpage><history><date date-type='received'><day>25</day><month>7</month><year>2013</year></date><date date-type='accepted'><day>9</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Jaussent et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Jaussent et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type='open-access' xlink:href='http://creativecommons.org/licenses/by/2.0'><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/2.0'>http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href='http://www.biomedcentral.com/1741-7015/11/212'></self-uri><abstract><sec><title>Background</title><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>Hypnotics are widely used by the elderly, and their impact on mortality remains controversial.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> The inconsistent findings could be due to methodological limitations, notably the lack of control for underlying sleep symptoms or illness associated with hypnotic use, for example, insomnia symptoms and excessive daytime sleepiness, depression and anxiety.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> Our objective was to examine the association between the use of hypnotics and mortality risk in a large cohort of community-dwelling elderly, taking into account a wide range of potential competing risks including sociodemographic characteristics, lifestyle, and chronic disorders as well as underlying psychiatric disorders and sleep complaints.</s></p></sec><sec><title>Methods</title><p><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Analyses were carried out on 6,696 participants aged 65 years or older randomly recruited from three French cities and free of dementia at baseline.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Adjusted Cox proportional hazards models with delayed entry, and age of the participants as the time scale, were used to determine the association between hypnotic use and 12-year survival.</s></p></sec><sec><title>Results</title><p><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>At baseline, 21.7% of the participants regularly used at least one hypnotic.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> During follow-up, 1,307 persons died, 480 from cancer and 344 from cardiovascular disease.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Analyses adjusted for study center, age and gender showed a significantly greater risk of all-cause and cardiovascular-related mortality with hypnotics, particularly benzodiazepines, and this increased with the number of hypnotics used.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> None of these associations were significant in models adjusting for sociodemographic and lifestyle characteristics, chronic disorders including cardiovascular pathologies, sleep and psychiatric disorders.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Results remained unchanged when duration of past hypnotic intake or persistent versus intermittent use during follow-up were taken into account.</s></p></sec><sec><title>Conclusions</title><p><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>When controlling for a large range of potential confounders, the risk of mortality was not significantly associated with hypnotic use regardless of the type and duration.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Underlying psychiatric disorders appear to be the principal confounders of the observed association.</s></p></sec></abstract><kwd-group><kwd>Cohort studies</kwd><kwd>Elderly</kwd><kwd>Hypnotics</kwd><kwd>Mortality</kwd><kwd>Sleep disorders</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Sleep changes with advancing age; however, the high prevalence of insomnia in the older adult population is often due to associated age-related medical and psychosocial comorbidities and the frequent use of medications that may impact sleep <italic>per se</italic>[<xref rid='B1' ref-type='bibr'>1</xref>].</s><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Insomnia symptoms in older adults are frequently associated with daytime fatigue, excessive daytime sleepiness (EDS), and hypnotics use[<xref rid='B2' ref-type='bibr'>2</xref>-<xref rid='B4' ref-type='bibr'>4</xref>].</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Insomnia and EDS are also frequently comorbid with other pathologies, notably cardiovascular diseases (CVD)
[<xref rid='B5' ref-type='bibr'>5</xref>,<xref rid='B6' ref-type='bibr'>6</xref>] and psychiatric disorder, for example, anxiety and depression
[<xref rid='B2' ref-type='bibr'>2</xref>,<xref rid='B4' ref-type='bibr'>4</xref>,<xref rid='B7' ref-type='bibr'>7</xref>].</s></p><p><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Hypnotics are indicated for treating insomnia symptoms, including those associated with anxiety and depression, and may also be used together with antidepressant treatment.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The current use of hypnotics in the general population is estimated to range between 3.5% and 11.7%, doubling in elderly populations
[<xref rid='B8' ref-type='bibr'>8</xref>-<xref rid='B11' ref-type='bibr'>11</xref>].</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Hypnotics may produce residual daytime sleepiness and impairment of psychomotor, attention and memory performances the day after bedtime administration, especially with the high dose and long half-life durations
[<xref rid='B12' ref-type='bibr'>12</xref>].</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Moreover, the use of hypnotics seems to be associated with excess risk of accidents such as falls and car accidents
[<xref rid='B12' ref-type='bibr'>12</xref>] and may increase mortality risk, especially in elderly people with increased pharmacodynamic alterations.</s></p><p><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>However, the high rate of insomnia, EDS complaints, and psychiatric disorder in the elderly, their frequent comorbidity, and the potential risk of mortality associated with both sleep disorders
[<xref rid='B13' ref-type='bibr'>13</xref>] and psychiatric disorders
[<xref rid='B14' ref-type='bibr'>14</xref>,<xref rid='B15' ref-type='bibr'>15</xref>] may override hypnotics as the cause of increased mortality, independently of the underlying burden of illness.</s></p><p><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>Overall, evidence suggesting an association between hypnotics consumption and mortality in the elderly remains controversial.</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Four observational studies in young adults
[<xref rid='B16' ref-type='bibr'>16</xref>,<xref rid='B17' ref-type='bibr'>17</xref>] and elderly people
[<xref rid='B18' ref-type='bibr'>18</xref>,<xref rid='B19' ref-type='bibr'>19</xref>] found no significant associations between hypnotics and all-cause mortality.</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Other studies reported a significant association with excessive all-cause deaths in adults
[<xref rid='B20' ref-type='bibr'>20</xref>-<xref rid='B22' ref-type='bibr'>22</xref>].</s><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Two large studies with very wide age ranges from young adult to older elderly people
[<xref rid='B23' ref-type='bibr'>23</xref>-<xref rid='B25' ref-type='bibr'>25</xref>] found significant associations in all age groups, including the elderly.</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Most of the above studies controlled for sociodemographic characteristics, lifestyle, and some chronic disorders but rarely or not at all for the underlying medical conditions associated with hypnotic prescription, that is depression, antidepressant use, anxiety, insomnia, and EDS.</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Finally, no studies examined the cumulative effect of hypnotics or the impact of their long-term use on mortality risk in an elderly population specifically.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> Several methodological issues may contribute to the observed inconsistencies, including the design of the study (retrospective or prospective); the duration of follow-up (between 2.5 and 20 years); the heterogeneity in sample size and age range; the type and duration of hypnotic prescription; and the lack of control for psychiatric and sleep disorders (prescription/indication biases).</s></p><p><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>The aim of the present study is to examine the associations between the use of hypnotics and 12-year mortality risk (all-causes, cancer and CVD) in a large cohort of community-dwelling elderly people, taking into account a wide range of potential competing risks including sociodemographic characteristics, lifestyle, and chronic disorders as well as underlying psychiatric disorders, EDS, and insomnia complaints.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> The impact of duration and type of hypnotic treatment were also evaluated.</s></p></sec><sec sec-type='methods'><title>Methods</title><sec><title>Study population</title><p><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>Participants were recruited as part of the Three-City Study, an ongoing multi-site longitudinal study involving three French cities: Bordeaux, Dijon and Montpellier
[<xref rid='B26' ref-type='bibr'>26</xref>].</s><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> Briefly, non-institutionalized participants aged 65 years or over were randomly selected from electoral rolls between 1999 and 2001.</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1> The acceptance rate was 37%, yielding a sample of 9,294 individuals.</s></p><p><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The study protocol was approved by the ethical committee of the University Hospital of Kremlin-Bicêtre and CPP Sud Méditérannée III, and written informed consent was obtained from each participant.</s><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The participants were administered standardized questionnaires and underwent clinical examinations at baseline and after 2, 4, 8, 10 and 12 years.</s></p></sec><sec><title>Mortality</title><p><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The exact date of death of the participants was obtained from death registries.</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The causes of death were collected by the local study centers from medical records and interviews with family physicians, clinicians and other non-medical informants (relatives or caregivers)
[<xref rid='B27' ref-type='bibr'>27</xref>].</s><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> A validation committee used all information to classify the cause of death using the tenth revision of International Classification of Diseases (ICD-10)
[<xref rid='B28' ref-type='bibr'>28</xref>] as follows: cancer (ICD-10: C00 to C97 and D37 to D48), coronary heart disease and stroke (ICD-10: I00 to I99 and R960 to R961), respiratory (ICD-10: J00 to J99), and ill-defined causes (ICD-10: R00 to R99).</s></p></sec><sec><title>Sociodemographic and clinical variables at baseline</title><p><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The standardized interview included questions on demographic characteristics, level of education, living alone, and on health behaviors (for example, consumption of alcohol and smoking status).</s><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Information on the health of the participants was obtained through detailed medical questionnaires.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Case-level depressive symptoms were defined as a score above the 16-point cut-off on the Center for Epidemiological Studies-Depression Scale
[<xref rid='B29' ref-type='bibr'>29</xref>].</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Anxiety trait symptoms were measured using the Spielberger’s State-Trait Anxiety Inventory
[<xref rid='B30' ref-type='bibr'>30</xref>].</s><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In the absence of a validated cut-off score in elderly populations, the state score was divided into tertiles with the highest tertile (higher level of anxiety) being compared to the two lowest tertiles.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Global cognitive function was assessed by the Mini-Mental State Examination
[<xref rid='B31' ref-type='bibr'>31</xref>] and participants scoring less than 26 were classified as cognitively impaired.</s><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Confinement was defined as social restriction (confinement to bed, home or outings restricted to the neighborhood)
[<xref rid='B32' ref-type='bibr'>32</xref>].</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Body mass index (BMI) was calculated as weight (kg) divided by height squared (m<sup>2</sup>).</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The presence of hypertension was defined by measured systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥95 mmHg or current antihypertensive treatment.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Diabetes was defined as fasting glucose level ≥7.0 mmol/l or treatment for diabetes.</s><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Hypercholesterolemia was defined as total cholesterol level ≥6.2 mmol/L or treatment with lipid-lowering agents.</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Detailed medical questionnaires included past history of respiratory and thyroid disorders, and cardio-cerebrovascular disease (angina pectoris, myocardial infarction, cardiovascular surgery, arteritis, and stroke) established according to standardized questions.</s></p></sec><sec><title>Sleep complaints at baseline</title><p><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Sleep complaints were assessed at baseline as part of the clinical interview, followed by the completion of a specific sleep questionnaire
[<xref rid='B33' ref-type='bibr'>33</xref>].</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The participants self-rated as ‘never, rarely, frequently, or often’ occurrence of being excessively sleepy during the day (EDS), having difficulties in initiating sleep (DIS), having several awakenings during the night (difficulties in maintaining sleep; DMS), having early morning awakening (EMA) without being able to go back to sleep, and snoring loudly.</s><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In this analysis, EDS was defined as reporting frequently or often being excessively sleepy.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Insomnia complaints based on DIS, DMS, and EMA were dichotomized as frequently/often versus never/rarely and summed up to obtain a number of insomnia complaints ranging from 0 to 3.</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The risk of obstructive sleep apnea syndrome (OSAS) was defined clinically as being obese (BMI ≥30 kg/m<sup>2</sup>), with frequent/often EDS, and frequent/often loud snoring.</s></p></sec><sec><title>Medications and hypnotic use</title><p><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>At baseline and at 2, 4, and 8-year follow-up, an inventory of all prescriptions and over-the-counter drugs used during the preceding month was included in a standardized interview.</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> Medical prescriptions and the medications themselves were checked by the interviewer, thus minimizing exposure misclassification.</s><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Current use of antidepressants and hypnotics were coded according to the World Health Organization’s Anatomical Therapeutic Chemical Classification
[<xref rid='B34' ref-type='bibr'>34</xref>].</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Hypnotics were classified as; benzodiazepines (BZD), BZD-like compounds (zolpidem, zopiclone), and miscellaneous medications (including barbiturates, antihistamines, and other pharmacological categories such as neuroleptics).</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> At baseline, the participants currently taking hypnotics were also requested to report the duration of hypnotic intake.</s></p></sec><sec><title>Statistical analyses</title><p><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Logistic regression models were used to compare the characteristics of participants according to the use of hypnotics at baseline after adjustment for study center, age, and gender.</s><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> To analyze the associations between hypnotic use and risk of mortality, Cox proportional hazard models with delayed entry and age of the participants as the time scale were used to estimate hazard ratios (HR) and their 95% confidence intervals (CI).</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This method gives better adjustment for age and is therefore preferable for a sample of elderly individuals over the standard model that uses study time as the time scale, because the covariates are strongly associated with age (for example, chronic diseases)
[<xref rid='B35' ref-type='bibr'>35</xref>,<xref rid='B36' ref-type='bibr'>36</xref>].</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Multivariate models included covariates that were associated with mortality at a conservative level of <italic>P</italic> &lt;0.15.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Model 1 was adjusted for study center, age, and gender.</s><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Model 2 was further adjusted for education, alcohol intake, smoking status, BMI, confinement, respiratory disorder, cognitive impairment, history of CVD, hypertension, and diabetes.</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Two other models were adjusted for diseases associated with hypnotic use to take into account possible prescription bias, for example, number of insomnia complaints and EDS (model 3); and anxiety, depressive symptomatology, and antidepressant use (model 4).</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The multivariate model 5 was adjusted for all possible confounders.</s><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> All-cause mortality was the principal outcome defined for the analysis.</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In secondary analyses, cause-specific mortality due to CVD and cancer was analyzed for separate end points.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> If both CVD and cancer were reported as cause of death, both causes were considered in the analysis.</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> In all final models, significance level was set at <italic>P</italic> &lt;0.05.</s><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Analyses were performed using SAS statistical software (version 9.2; SAS Inc, Cary, NC, USA).</s></p></sec></sec><sec sec-type='results'><title>Results</title><sec><title>Study population</title><p><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obj1' type='Obj'></CoreSc1>As shown in the study diagram (Figure 
<xref rid='F1' ref-type='fig'>1</xref>), the study sample included 6,696 participants free of dementia (58.7% women) with a median age of 72.8 years (range, 65.0 to 95.0 years).</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> The 2,382 participants free of dementia excluded from the study were significantly more likely to be older, have a lower education level, were more frequently female and living alone, with confinement, hypertension, diabetes, respiratory disease, hypercholesterolemia, depressive and anxiety symptoms, cognitive impairment, past history of cardio-cerebrovascular disease, and taking more hypnotics (<italic>P</italic> &lt;0.05 for all comparisons).</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Exp1' type='Exp'></CoreSc1> They were also more likely to have died during the follow-up period (<italic>P</italic> &lt;0.0001).</s></p><fig id='F1' position='float'><label>Figure 1</label><caption><p><bold>Flow diagram.</bold><sup>(1)</sup> For 41 participants, the cause of death was related to both cardiovascular and cancerb.</p></caption><graphic xlink:href='1741-7015-11-212-1'></graphic></fig><p><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>At baseline, 21.7% of the participants (n = 1,454) were taking at least one hypnotic, 6.9% (n = 464) had three insomnia complaints, and 3.9% (n = 260) had no insomnia complaints.</s><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> More than 3% (n = 212) reported taking two or more hypnotics.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Regarding the main classes of hypnotics, 16% (n = 1070) took BZD, 4.8% (n = 321) BZD-like compounds, and 3.0% (n = 204) miscellaneous medications (of whom 54.4% took antihistamines, 25.0% non-BZD anxiolytics, 18.6% barbiturates, and 4.4% neuroleptics).</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> With regard to duration, 4.8% (n = 304) had been taking hypnotics for less than 5 years, 3.9% (n = 244) between 5 and 10 years, 2.0% (n = 127) between 10 and 20 years, and 6.0% (n = 378) for more than 20 years.</s></p><p><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Baseline sociodemographic and clinical characteristics of the participants according to hypnotic use are described in Table 
<xref rid='T1' ref-type='table'>1</xref>.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> An analysis adjusted for study center, age, and gender showed that participants taking hypnotics had a lower education level; were more likely to be confined to home; had more symptoms of depression, anxiety, and cognitive impairment; more frequently had a past history of chronic disease (CVD, thyroid disease, diabetes, hypercholesterolemia); consumed less caffeine; and reported more insomnia complaints and EDS (<italic>P</italic> &lt;0.05 for all comparisons).</s></p><table-wrap position='float' id='T1'><label>Table 1</label><caption><p>Sociodemographic and clinical characteristics of participants according to hypnotic use at baseline</p></caption><table border='1' rules='groups' frame='hsides'><colgroup><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col></colgroup><thead valign='top'><tr><th rowspan='2' valign='bottom' align='left'> <hr></hr></th><th rowspan='2' valign='bottom' align='left'> <hr></hr></th><th colspan='4' valign='bottom' align='center'><bold>Hypnotic use</bold><hr></hr></th><th rowspan='2' valign='bottom' align='left'> <hr></hr></th><th rowspan='2' valign='bottom' align='left'> <hr></hr></th></tr><tr><th colspan='2' valign='bottom' align='center'><bold>No N = 5,242</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Yes N = 1,454</bold><hr></hr></th></tr><tr><th align='left'><bold>Variable</bold></th><th align='left'> </th><th align='left'><bold>n</bold></th><th align='left'><bold>%</bold></th><th align='left'><bold>n</bold></th><th align='left'><bold>%</bold></th><th align='left'><bold>Odds ratio [95% CI]</bold><sup><bold>a</bold></sup></th><th align='left'><bold><italic>P</italic></bold></th></tr></thead><tbody valign='top'><tr><td valign='bottom' align='left'>High level of education<sup>b</sup><hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,136<hr></hr></td><td valign='bottom' align='left'>78.90<hr></hr></td><td valign='bottom' align='left'>1,245<hr></hr></td><td valign='bottom' align='left'>85.63<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.0006<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>1,106<hr></hr></td><td valign='bottom' align='left'>21.10<hr></hr></td><td valign='bottom' align='left'>209<hr></hr></td><td valign='bottom' align='left'>14.37<hr></hr></td><td valign='bottom' align='left'>0.75 [0.63;0.88]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Living alone<hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>1,610<hr></hr></td><td valign='bottom' align='left'>30.71<hr></hr></td><td valign='bottom' align='left'>605<hr></hr></td><td valign='bottom' align='left'>41.61<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.06<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>3,632<hr></hr></td><td valign='bottom' align='left'>69.29<hr></hr></td><td valign='bottom' align='left'>849<hr></hr></td><td valign='bottom' align='left'>58.39<hr></hr></td><td valign='bottom' align='left'>0.88 [0.77;1.01]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Confinement<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>5,025<hr></hr></td><td valign='bottom' align='left'>95.86<hr></hr></td><td valign='bottom' align='left'>1,314<hr></hr></td><td valign='bottom' align='left'>90.37<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>217<hr></hr></td><td valign='bottom' align='left'>4.14<hr></hr></td><td valign='bottom' align='left'>140<hr></hr></td><td valign='bottom' align='left'>9.63<hr></hr></td><td valign='bottom' align='left'>1.90 [1.51;2.40]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Alcohol intake (g/day)<hr></hr></td><td valign='bottom' align='left'>&lt;12<hr></hr></td><td valign='bottom' align='left'>955<hr></hr></td><td valign='bottom' align='left'>18.22<hr></hr></td><td valign='bottom' align='left'>349<hr></hr></td><td valign='bottom' align='left'>24.00<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.14<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>12 to 36<hr></hr></td><td valign='bottom' align='left'>3,799<hr></hr></td><td valign='bottom' align='left'>72.47<hr></hr></td><td valign='bottom' align='left'>1,012<hr></hr></td><td valign='bottom' align='left'>69.60<hr></hr></td><td valign='bottom' align='left'>0.86 [0.75;1.00]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>&gt;36<hr></hr></td><td valign='bottom' align='left'>488<hr></hr></td><td valign='bottom' align='left'>9.31<hr></hr></td><td valign='bottom' align='left'>93<hr></hr></td><td valign='bottom' align='left'>6.40<hr></hr></td><td valign='bottom' align='left'>0.92 [0.70;1.22]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Caffeine intake (mg/day)<hr></hr></td><td valign='bottom' align='left'>≤125<hr></hr></td><td valign='bottom' align='left'>1,310<hr></hr></td><td valign='bottom' align='left'>24.99<hr></hr></td><td valign='bottom' align='left'>423<hr></hr></td><td valign='bottom' align='left'>29.09<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.007<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>125 to 375<hr></hr></td><td valign='bottom' align='left'>3,103<hr></hr></td><td valign='bottom' align='left'>59.19<hr></hr></td><td valign='bottom' align='left'>836<hr></hr></td><td valign='bottom' align='left'>57.50<hr></hr></td><td valign='bottom' align='left'>0.83 [0.73;0.95]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>&gt;375<hr></hr></td><td valign='bottom' align='left'>829<hr></hr></td><td valign='bottom' align='left'>15.81<hr></hr></td><td valign='bottom' align='left'>195<hr></hr></td><td valign='bottom' align='left'>13.41<hr></hr></td><td valign='bottom' align='left'>0.76 [0.62;0.92]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Smoking status<hr></hr></td><td valign='bottom' align='left'>Never<hr></hr></td><td valign='bottom' align='left'>3,033<hr></hr></td><td valign='bottom' align='left'>57.86<hr></hr></td><td valign='bottom' align='left'>969<hr></hr></td><td valign='bottom' align='left'>66.64<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.38<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Past<hr></hr></td><td valign='bottom' align='left'>1,901<hr></hr></td><td valign='bottom' align='left'>36.26<hr></hr></td><td valign='bottom' align='left'>402<hr></hr></td><td valign='bottom' align='left'>27.65<hr></hr></td><td valign='bottom' align='left'>0.99 [0.85;1.15]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Current<hr></hr></td><td valign='bottom' align='left'>308<hr></hr></td><td valign='bottom' align='left'>5.88<hr></hr></td><td valign='bottom' align='left'>83<hr></hr></td><td valign='bottom' align='left'>5.71<hr></hr></td><td valign='bottom' align='left'>1.19 [0.92;1.55]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>History of cardiovascular disease<sup>c</sup><hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>3,902<hr></hr></td><td valign='bottom' align='left'>74.44<hr></hr></td><td valign='bottom' align='left'>945<hr></hr></td><td valign='bottom' align='left'>64.99<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>1,340<hr></hr></td><td valign='bottom' align='left'>25.56<hr></hr></td><td valign='bottom' align='left'>509<hr></hr></td><td valign='bottom' align='left'>35.01<hr></hr></td><td valign='bottom' align='left'>1.59 [1.40;1.81]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Respiratory disease<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,945<hr></hr></td><td valign='bottom' align='left'>94.33<hr></hr></td><td valign='bottom' align='left'>1,364<hr></hr></td><td valign='bottom' align='left'>93.81<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.35<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>297<hr></hr></td><td valign='bottom' align='left'>5.67<hr></hr></td><td valign='bottom' align='left'>90<hr></hr></td><td valign='bottom' align='left'>6.19<hr></hr></td><td valign='bottom' align='left'>1.13 [0.88;1.44]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Thyroid disease<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,823<hr></hr></td><td valign='bottom' align='left'>92.01<hr></hr></td><td valign='bottom' align='left'>1,286<hr></hr></td><td valign='bottom' align='left'>88.45<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.009<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>419<hr></hr></td><td valign='bottom' align='left'>7.99<hr></hr></td><td valign='bottom' align='left'>168<hr></hr></td><td valign='bottom' align='left'>11.55<hr></hr></td><td valign='bottom' align='left'>1.29 [1.07;1.57]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Depressive symptomatology<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,295<hr></hr></td><td valign='bottom' align='left'>81.93<hr></hr></td><td valign='bottom' align='left'>897<hr></hr></td><td valign='bottom' align='left'>61.69<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>947<hr></hr></td><td valign='bottom' align='left'>18.07<hr></hr></td><td valign='bottom' align='left'>557<hr></hr></td><td valign='bottom' align='left'>38.31<hr></hr></td><td valign='bottom' align='left'>2.76 [2.41;3.15]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Antidepressants intake<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>5,081<hr></hr></td><td valign='bottom' align='left'>96.93<hr></hr></td><td valign='bottom' align='left'>1,196<hr></hr></td><td valign='bottom' align='left'>82.26<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>161<hr></hr></td><td valign='bottom' align='left'>3.07<hr></hr></td><td valign='bottom' align='left'>258<hr></hr></td><td valign='bottom' align='left'>17.74<hr></hr></td><td valign='bottom' align='left'>6.32 [5.12;7.81]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Spielberger trait anxiety<hr></hr></td><td valign='bottom' align='left'>&lt;43<hr></hr></td><td valign='bottom' align='left'>3,688<hr></hr></td><td valign='bottom' align='left'>70.35<hr></hr></td><td valign='bottom' align='left'>715<hr></hr></td><td valign='bottom' align='left'>49.17<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>≥43<hr></hr></td><td valign='bottom' align='left'>1,554<hr></hr></td><td valign='bottom' align='left'>29.65<hr></hr></td><td valign='bottom' align='left'>739<hr></hr></td><td valign='bottom' align='left'>50.83<hr></hr></td><td valign='bottom' align='left'>2.33 [2.06;2.64]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Mini Mental State Examination Score<hr></hr></td><td valign='bottom' align='left'>≥ 26<hr></hr></td><td valign='bottom' align='left'>4,559<hr></hr></td><td valign='bottom' align='left'>86.97<hr></hr></td><td valign='bottom' align='left'>1,190<hr></hr></td><td valign='bottom' align='left'>81.84<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>&lt;26<hr></hr></td><td valign='bottom' align='left'>683<hr></hr></td><td valign='bottom' align='left'>13.03<hr></hr></td><td valign='bottom' align='left'>264<hr></hr></td><td valign='bottom' align='left'>18.16<hr></hr></td><td valign='bottom' align='left'>1.40 [1.20;1.65]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Body mass index (kg/m<sup>2</sup>)<hr></hr></td><td valign='bottom' align='left'>Normal (&lt;25)<hr></hr></td><td valign='bottom' align='left'>2,477<hr></hr></td><td valign='bottom' align='left'>47.25<hr></hr></td><td valign='bottom' align='left'>747<hr></hr></td><td valign='bottom' align='left'>51.38<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.41<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Overweight (25 to 29)<hr></hr></td><td valign='bottom' align='left'>2,106<hr></hr></td><td valign='bottom' align='left'>40.18<hr></hr></td><td valign='bottom' align='left'>515<hr></hr></td><td valign='bottom' align='left'>35.42<hr></hr></td><td valign='bottom' align='left'>0.92 [0.81;1.05]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Obese (≥30)<hr></hr></td><td valign='bottom' align='left'>659<hr></hr></td><td valign='bottom' align='left'>12.57<hr></hr></td><td valign='bottom' align='left'>192<hr></hr></td><td valign='bottom' align='left'>13.20<hr></hr></td><td valign='bottom' align='left'>1.00 [0.83;1.20]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Hypertension<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>2,175<hr></hr></td><td valign='bottom' align='left'>41.49<hr></hr></td><td valign='bottom' align='left'>538<hr></hr></td><td valign='bottom' align='left'>37.00<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.08<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>3,067<hr></hr></td><td valign='bottom' align='left'>58.51<hr></hr></td><td valign='bottom' align='left'>916<hr></hr></td><td valign='bottom' align='left'>63.00<hr></hr></td><td valign='bottom' align='left'>1.12 [0.99;1.27]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Diabetes mellitus<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,777<hr></hr></td><td valign='bottom' align='left'>91.13<hr></hr></td><td valign='bottom' align='left'>1,314<hr></hr></td><td valign='bottom' align='left'>90.37<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.03<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>465<hr></hr></td><td valign='bottom' align='left'>8.87<hr></hr></td><td valign='bottom' align='left'>140<hr></hr></td><td valign='bottom' align='left'>9.63<hr></hr></td><td valign='bottom' align='left'>1.25 [1.02;1.54]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Hypercholesterolemia<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>3,349<hr></hr></td><td valign='bottom' align='left'>63.89<hr></hr></td><td valign='bottom' align='left'>859<hr></hr></td><td valign='bottom' align='left'>59.08<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.005<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>1,893<hr></hr></td><td valign='bottom' align='left'>36.11<hr></hr></td><td valign='bottom' align='left'>595<hr></hr></td><td valign='bottom' align='left'>40.92<hr></hr></td><td valign='bottom' align='left'>1.19 [1.05;1.34]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Snoring loudly (n = 5,972)<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>3,021<hr></hr></td><td valign='bottom' align='left'>64.30<hr></hr></td><td valign='bottom' align='left'>863<hr></hr></td><td valign='bottom' align='left'>67.74<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.63<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frequently/Often<hr></hr></td><td valign='bottom' align='left'>1,677<hr></hr></td><td valign='bottom' align='left'>35.70<hr></hr></td><td valign='bottom' align='left'>411<hr></hr></td><td valign='bottom' align='left'>32.26<hr></hr></td><td valign='bottom' align='left'>0.97 [0.84;1.11]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Difficulties in initiating sleep<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>3,760<hr></hr></td><td valign='bottom' align='left'>71.73<hr></hr></td><td valign='bottom' align='left'>641<hr></hr></td><td valign='bottom' align='left'>44.09<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frequently/Often<hr></hr></td><td valign='bottom' align='left'>1,482<hr></hr></td><td valign='bottom' align='left'>28.27<hr></hr></td><td valign='bottom' align='left'>813<hr></hr></td><td valign='bottom' align='left'>55.91<hr></hr></td><td valign='bottom' align='left'>2.85 [2.51;3.24]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Difficulties in maintaining sleep<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>2,029<hr></hr></td><td valign='bottom' align='left'>38.71<hr></hr></td><td valign='bottom' align='left'>455<hr></hr></td><td valign='bottom' align='left'>31.29<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frequently/Often<hr></hr></td><td valign='bottom' align='left'>3,213<hr></hr></td><td valign='bottom' align='left'>61.29<hr></hr></td><td valign='bottom' align='left'>999<hr></hr></td><td valign='bottom' align='left'>68.71<hr></hr></td><td valign='bottom' align='left'>1.29 [1.14;1.47]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Early morning awakening<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>3,565<hr></hr></td><td valign='bottom' align='left'>68.01<hr></hr></td><td valign='bottom' align='left'>740<hr></hr></td><td valign='bottom' align='left'>50.89<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frequently/Often<hr></hr></td><td valign='bottom' align='left'>1,677<hr></hr></td><td valign='bottom' align='left'>31.99<hr></hr></td><td valign='bottom' align='left'>714<hr></hr></td><td valign='bottom' align='left'>49.11<hr></hr></td><td valign='bottom' align='left'>1.85 [1.64;2.09]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Number of insomnia complaints<sup>d</sup><hr></hr></td><td valign='bottom' align='left'>0<hr></hr></td><td valign='bottom' align='left'>1,586<hr></hr></td><td valign='bottom' align='left'>30.26<hr></hr></td><td valign='bottom' align='left'>260<hr></hr></td><td valign='bottom' align='left'>17.88<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>1,729<hr></hr></td><td valign='bottom' align='left'>32.98<hr></hr></td><td valign='bottom' align='left'>326<hr></hr></td><td valign='bottom' align='left'>22.42<hr></hr></td><td valign='bottom' align='left'>1.15 [0.96;1.38]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>2<hr></hr></td><td valign='bottom' align='left'>1,138<hr></hr></td><td valign='bottom' align='left'>21.71<hr></hr></td><td valign='bottom' align='left'>404<hr></hr></td><td valign='bottom' align='left'>27.79<hr></hr></td><td valign='bottom' align='left'>2.02 [1.70;2.41]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>3<hr></hr></td><td valign='bottom' align='left'>789<hr></hr></td><td valign='bottom' align='left'>15.05<hr></hr></td><td valign='bottom' align='left'>464<hr></hr></td><td valign='bottom' align='left'>31.91<hr></hr></td><td valign='bottom' align='left'>3.07 [2.56;3.68]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Excessive daytime sleepiness<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>4,384<hr></hr></td><td valign='bottom' align='left'>83.63<hr></hr></td><td valign='bottom' align='left'>1,165<hr></hr></td><td valign='bottom' align='left'>80.12<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.005<hr></hr></td></tr><tr><td align='left'> </td><td align='left'>Frequently/Often</td><td align='left'>858</td><td align='left'>16.37</td><td align='left'>289</td><td align='left'>19.88</td><td align='left'>1.25 [1.07;1.47]</td><td align='left'> </td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Adjustment for center study, age and gender; <sup>b</sup>university level; <sup>c</sup>history of cardiovascular disease (stroke or coronary heart disease); <sup>d</sup>number of insomnia complaints: difficulties in initiating sleep + difficulties in maintaining sleep + early morning awakening. CI, confidence interval.</p></table-wrap-foot></table-wrap></sec><sec><title>Association between hypnotic use and 12-year mortality</title><p><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The median follow-up time for the study was 8.9 years with a range of 0.06 to 11.7 years.</s><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> During this period, 1,307 (19.5%) deaths were observed.</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> They were particularly related to CVD (26.3%), cancer (36.8%), and co-morbid CVD and cancer (3.1%).</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A substantial number of deaths were due to ill-defined causes (21.6%) as the result of multiple pathologies associated with frailty, and 10.2% died from respiratory diseases.</s></p><p><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Baseline sociodemographic and clinical characteristics in relation to follow-up mortality (all causes) are given in Table 
<xref rid='T2' ref-type='table'>2</xref>.</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> Participants who died during follow-up were more frequently confined to home, obese, past or current smoker, consuming less alcohol, had hypertension, diabetes mellitus, a past history of CVD, respiratory disease, poorer cognitive performance, EDS, depressive symptoms, or were taking antidepressants.</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> They also tended to have a lower level of education, and more frequently reported insomnia and anxiety symptoms (<italic>P</italic> &lt;0.15).</s><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Subsequent analyses were adjusted for these factors.</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A significant association was also found for participants at risk of OSAS (n = 133; HR = 1.76; 95% CI = 1.31, 2.36; <italic>P</italic> = 0.0002).</s></p><table-wrap position='float' id='T2'><label>Table 2</label><caption><p>Baseline predictors of deaths from all causes during follow-up</p></caption><table border='1' rules='groups' frame='hsides'><colgroup><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col><col align='left'></col></colgroup><thead valign='top'><tr><th valign='bottom' align='left'> <hr></hr></th><th valign='bottom' align='left'> <hr></hr></th><th colspan='4' valign='bottom' align='center'><bold>Deaths-all causes</bold><hr></hr></th><th valign='bottom' align='left'> <hr></hr></th><th valign='bottom' align='left'> <hr></hr></th></tr><tr><th valign='bottom' align='left'> <hr></hr></th><th valign='bottom' align='left'> <hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>No N = 5,389</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Yes N = 1,307</bold><hr></hr></th><th valign='bottom' align='left'> <hr></hr></th><th valign='bottom' align='left'> <hr></hr></th></tr><tr><th align='left'><bold>Variable</bold></th><th align='left'> </th><th align='left'><bold>n</bold></th><th align='left'><bold>%</bold></th><th align='left'><bold>n</bold></th><th align='left'><bold>%</bold></th><th align='left'><bold>Hazard ratio [95% CI]</bold><sup><bold>a</bold></sup></th><th align='left'><bold><italic>P</italic></bold><sup><bold>a</bold></sup></th></tr></thead><tbody valign='top'><tr><td valign='bottom' align='left'>High level of education<sup>b</sup><hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,337<hr></hr></td><td valign='bottom' align='left'>80.48<hr></hr></td><td valign='bottom' align='left'>1,044<hr></hr></td><td valign='bottom' align='left'>79.88<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.06<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>1,052<hr></hr></td><td valign='bottom' align='left'>19.52<hr></hr></td><td valign='bottom' align='left'>263<hr></hr></td><td valign='bottom' align='left'>20.12<hr></hr></td><td valign='bottom' align='left'>0.87 [0.76;1.00]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Living alone<hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>1,782<hr></hr></td><td valign='bottom' align='left'>33.07<hr></hr></td><td valign='bottom' align='left'>433<hr></hr></td><td valign='bottom' align='left'>33.13<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.84<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>3,607<hr></hr></td><td valign='bottom' align='left'>66.93<hr></hr></td><td valign='bottom' align='left'>874<hr></hr></td><td valign='bottom' align='left'>66.87<hr></hr></td><td valign='bottom' align='left'>1.01 [0.89;1.15]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Confinement<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>5,181<hr></hr></td><td valign='bottom' align='left'>96.14<hr></hr></td><td valign='bottom' align='left'>1,158<hr></hr></td><td valign='bottom' align='left'>88.60<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>208<hr></hr></td><td valign='bottom' align='left'>3.86<hr></hr></td><td valign='bottom' align='left'>149<hr></hr></td><td valign='bottom' align='left'>11.40<hr></hr></td><td valign='bottom' align='left'>1.78 [1.49;2.13]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Alcohol intake (g/day)<hr></hr></td><td valign='bottom' align='left'>&lt;12<hr></hr></td><td valign='bottom' align='left'>1,062<hr></hr></td><td valign='bottom' align='left'>19.71<hr></hr></td><td valign='bottom' align='left'>242<hr></hr></td><td valign='bottom' align='left'>18.52<hr></hr></td><td valign='bottom' align='left'>1.23 [1.06;1.42]<hr></hr></td><td valign='bottom' align='left'>0.01<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>12 to 36<hr></hr></td><td valign='bottom' align='left'>3,900<hr></hr></td><td valign='bottom' align='left'>72.37<hr></hr></td><td valign='bottom' align='left'>911<hr></hr></td><td valign='bottom' align='left'>69.70<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>&gt;36<hr></hr></td><td valign='bottom' align='left'>427<hr></hr></td><td valign='bottom' align='left'>7.92<hr></hr></td><td valign='bottom' align='left'>154<hr></hr></td><td valign='bottom' align='left'>11.78<hr></hr></td><td valign='bottom' align='left'>1.14 [0.96;1.36]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Caffeine intake (mg/day)<hr></hr></td><td valign='bottom' align='left'>≤125<hr></hr></td><td valign='bottom' align='left'>1,362<hr></hr></td><td valign='bottom' align='left'>25.27<hr></hr></td><td valign='bottom' align='left'>371<hr></hr></td><td valign='bottom' align='left'>28.39<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.86<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>125 to 375<hr></hr></td><td valign='bottom' align='left'>3,164<hr></hr></td><td valign='bottom' align='left'>58.71<hr></hr></td><td valign='bottom' align='left'>775<hr></hr></td><td valign='bottom' align='left'>59.30<hr></hr></td><td valign='bottom' align='left'>0.97 [0.85;1.09]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>&gt;375<hr></hr></td><td valign='bottom' align='left'>863<hr></hr></td><td valign='bottom' align='left'>16.01<hr></hr></td><td valign='bottom' align='left'>161<hr></hr></td><td valign='bottom' align='left'>12.32<hr></hr></td><td valign='bottom' align='left'>0.97 [0.81;1.17]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Smoking status<hr></hr></td><td valign='bottom' align='left'>Never<hr></hr></td><td valign='bottom' align='left'>3,368<hr></hr></td><td valign='bottom' align='left'>62.50<hr></hr></td><td valign='bottom' align='left'>634<hr></hr></td><td valign='bottom' align='left'>48.51<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>&lt;0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Past<hr></hr></td><td valign='bottom' align='left'>1,740<hr></hr></td><td valign='bottom' align='left'>32.29<hr></hr></td><td valign='bottom' align='left'>563<hr></hr></td><td valign='bottom' align='left'>43.08<hr></hr></td><td valign='bottom' align='left'>1.22 [1.07;1.40]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Current<hr></hr></td><td valign='bottom' align='left'>281<hr></hr></td><td valign='bottom' align='left'>5.21<hr></hr></td><td valign='bottom' align='left'>110<hr></hr></td><td valign='bottom' align='left'>8.42<hr></hr></td><td valign='bottom' align='left'>1.73 [1.41;2.14]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>History of cardiovascular disease<sup>c</sup><hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,079<hr></hr></td><td valign='bottom' align='left'>75.69<hr></hr></td><td valign='bottom' align='left'>768<hr></hr></td><td valign='bottom' align='left'>58.76<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>1,310<hr></hr></td><td valign='bottom' align='left'>24.31<hr></hr></td><td valign='bottom' align='left'>539<hr></hr></td><td valign='bottom' align='left'>41.24<hr></hr></td><td valign='bottom' align='left'>1.49 [1.33;1.67]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Respiratory disease<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>5,121<hr></hr></td><td valign='bottom' align='left'>95.03<hr></hr></td><td valign='bottom' align='left'>1,188<hr></hr></td><td valign='bottom' align='left'>90.90<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>268<hr></hr></td><td valign='bottom' align='left'>4.97<hr></hr></td><td valign='bottom' align='left'>119<hr></hr></td><td valign='bottom' align='left'>9.10<hr></hr></td><td valign='bottom' align='left'>1.64 [1.36;1.98]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Thyroid disease<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,890<hr></hr></td><td valign='bottom' align='left'>90.74<hr></hr></td><td valign='bottom' align='left'>1,219<hr></hr></td><td valign='bottom' align='left'>93.27<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.19<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>499<hr></hr></td><td valign='bottom' align='left'>9.26<hr></hr></td><td valign='bottom' align='left'>88<hr></hr></td><td valign='bottom' align='left'>6.73<hr></hr></td><td valign='bottom' align='left'>1.16 [0.93;1.45]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Depressive symptomatology<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,209<hr></hr></td><td valign='bottom' align='left'>78.10<hr></hr></td><td valign='bottom' align='left'>983<hr></hr></td><td valign='bottom' align='left'>75.21<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.0005<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>1,180<hr></hr></td><td valign='bottom' align='left'>21.90<hr></hr></td><td valign='bottom' align='left'>324<hr></hr></td><td valign='bottom' align='left'>24.79<hr></hr></td><td valign='bottom' align='left'>1.26 [1.11;1.43]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Antidepressant use<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>5,072<hr></hr></td><td valign='bottom' align='left'>94.12<hr></hr></td><td valign='bottom' align='left'>1,205<hr></hr></td><td valign='bottom' align='left'>92.20<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.0002<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>317<hr></hr></td><td valign='bottom' align='left'>5.88<hr></hr></td><td valign='bottom' align='left'>102<hr></hr></td><td valign='bottom' align='left'>7.80<hr></hr></td><td valign='bottom' align='left'>1.47 [1.20;1.80]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Spielberger trait anxiety<hr></hr></td><td valign='bottom' align='left'>&lt;43<hr></hr></td><td valign='bottom' align='left'>3,509<hr></hr></td><td valign='bottom' align='left'>65.11<hr></hr></td><td valign='bottom' align='left'>894<hr></hr></td><td valign='bottom' align='left'>68.40<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.13<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>≥43<hr></hr></td><td valign='bottom' align='left'>1,880<hr></hr></td><td valign='bottom' align='left'>34.89<hr></hr></td><td valign='bottom' align='left'>413<hr></hr></td><td valign='bottom' align='left'>31.60<hr></hr></td><td valign='bottom' align='left'>1.10 [0.97;1.23]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Mini Mental State Examination Score<hr></hr></td><td valign='bottom' align='left'>≥ 26<hr></hr></td><td valign='bottom' align='left'>4,666<hr></hr></td><td valign='bottom' align='left'>86.58<hr></hr></td><td valign='bottom' align='left'>1,083<hr></hr></td><td valign='bottom' align='left'>82.86<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.005<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>&lt;26<hr></hr></td><td valign='bottom' align='left'>723<hr></hr></td><td valign='bottom' align='left'>13.42<hr></hr></td><td valign='bottom' align='left'>224<hr></hr></td><td valign='bottom' align='left'>17.14<hr></hr></td><td valign='bottom' align='left'>1.23 [1.07;1.43]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Body mass index (kg/m<sup>2</sup>)<hr></hr></td><td valign='bottom' align='left'>Normal (&lt;25)<hr></hr></td><td valign='bottom' align='left'>2,611<hr></hr></td><td valign='bottom' align='left'>48.45<hr></hr></td><td valign='bottom' align='left'>613<hr></hr></td><td valign='bottom' align='left'>46.90<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.0007<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Overweight (25 to 29)<hr></hr></td><td valign='bottom' align='left'>2,118<hr></hr></td><td valign='bottom' align='left'>39.30<hr></hr></td><td valign='bottom' align='left'>503<hr></hr></td><td valign='bottom' align='left'>38.49<hr></hr></td><td valign='bottom' align='left'>1.01 [0.90;1.14]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Obese (≥30)<hr></hr></td><td valign='bottom' align='left'>660<hr></hr></td><td valign='bottom' align='left'>12.25<hr></hr></td><td valign='bottom' align='left'>191<hr></hr></td><td valign='bottom' align='left'>14.61<hr></hr></td><td valign='bottom' align='left'>1.36 [1.15;1.60]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Hypertension<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>2,313<hr></hr></td><td valign='bottom' align='left'>42.92<hr></hr></td><td valign='bottom' align='left'>400<hr></hr></td><td valign='bottom' align='left'>30.60<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.002<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>3,076<hr></hr></td><td valign='bottom' align='left'>57.08<hr></hr></td><td valign='bottom' align='left'>907<hr></hr></td><td valign='bottom' align='left'>69.40<hr></hr></td><td valign='bottom' align='left'>1.21 [1.07;1.36]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Diabetes mellitus<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>4,965<hr></hr></td><td valign='bottom' align='left'>92.13<hr></hr></td><td valign='bottom' align='left'>1,126<hr></hr></td><td valign='bottom' align='left'>86.15<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.0001<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>424<hr></hr></td><td valign='bottom' align='left'>7.87<hr></hr></td><td valign='bottom' align='left'>181<hr></hr></td><td valign='bottom' align='left'>13.85<hr></hr></td><td valign='bottom' align='left'>1.58 [1.35;1.85]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Hypercholesterolemia<hr></hr></td><td valign='bottom' align='left'>No<hr></hr></td><td valign='bottom' align='left'>3,333<hr></hr></td><td valign='bottom' align='left'>61.85<hr></hr></td><td valign='bottom' align='left'>875<hr></hr></td><td valign='bottom' align='left'>66.95<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.99<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Yes<hr></hr></td><td valign='bottom' align='left'>2,056<hr></hr></td><td valign='bottom' align='left'>38.15<hr></hr></td><td valign='bottom' align='left'>432<hr></hr></td><td valign='bottom' align='left'>33.05<hr></hr></td><td valign='bottom' align='left'>1.00 [0.89;1.12]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Snoring loudly (n = 5,972)<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>3,114<hr></hr></td><td valign='bottom' align='left'>64.93<hr></hr></td><td valign='bottom' align='left'>770<hr></hr></td><td valign='bottom' align='left'>65.48<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.90<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frequently/Often<hr></hr></td><td valign='bottom' align='left'>1,682<hr></hr></td><td valign='bottom' align='left'>35.07<hr></hr></td><td valign='bottom' align='left'>406<hr></hr></td><td valign='bottom' align='left'>34.52<hr></hr></td><td valign='bottom' align='left'>1.01 [0.89;1.14]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Difficulties in initiating sleep<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>3,506<hr></hr></td><td valign='bottom' align='left'>65.06<hr></hr></td><td valign='bottom' align='left'>895<hr></hr></td><td valign='bottom' align='left'>68.48<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.20<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frequently/Often<hr></hr></td><td valign='bottom' align='left'>1,883<hr></hr></td><td valign='bottom' align='left'>34.94<hr></hr></td><td valign='bottom' align='left'>412<hr></hr></td><td valign='bottom' align='left'>31.52<hr></hr></td><td valign='bottom' align='left'>0.92 [0.81;1.04]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Difficulties in maintaining sleep<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>2,055<hr></hr></td><td valign='bottom' align='left'>38.13<hr></hr></td><td valign='bottom' align='left'>429<hr></hr></td><td valign='bottom' align='left'>32.82<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.26<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frequently/Often<hr></hr></td><td valign='bottom' align='left'>3,334<hr></hr></td><td valign='bottom' align='left'>61.87<hr></hr></td><td valign='bottom' align='left'>878<hr></hr></td><td valign='bottom' align='left'>67.18<hr></hr></td><td valign='bottom' align='left'>1.07 [0.95;1.20]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Early morning awakening<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>3,434<hr></hr></td><td valign='bottom' align='left'>63.72<hr></hr></td><td valign='bottom' align='left'>871<hr></hr></td><td valign='bottom' align='left'>66.64<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.12<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>Frequently/Often<hr></hr></td><td valign='bottom' align='left'>1,955<hr></hr></td><td valign='bottom' align='left'>36.28<hr></hr></td><td valign='bottom' align='left'>436<hr></hr></td><td valign='bottom' align='left'>33.36<hr></hr></td><td valign='bottom' align='left'>0.91 [0.81;1.02]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Number of insomnia complaints<sup>d</sup><hr></hr></td><td valign='bottom' align='left'>0<hr></hr></td><td valign='bottom' align='left'>1,526<hr></hr></td><td valign='bottom' align='left'>28.32<hr></hr></td><td valign='bottom' align='left'>320<hr></hr></td><td valign='bottom' align='left'>24.48<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.07<hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>1,595<hr></hr></td><td valign='bottom' align='left'>29.60<hr></hr></td><td valign='bottom' align='left'>460<hr></hr></td><td valign='bottom' align='left'>35.20<hr></hr></td><td valign='bottom' align='left'>1.14 [0.99;1.31]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>2<hr></hr></td><td valign='bottom' align='left'>1,227<hr></hr></td><td valign='bottom' align='left'>22.77<hr></hr></td><td valign='bottom' align='left'>315<hr></hr></td><td valign='bottom' align='left'>24.10<hr></hr></td><td valign='bottom' align='left'>1.08 [0.92;1.26]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> <hr></hr></td><td valign='bottom' align='left'>3<hr></hr></td><td valign='bottom' align='left'>1,041<hr></hr></td><td valign='bottom' align='left'>19.32<hr></hr></td><td valign='bottom' align='left'>212<hr></hr></td><td valign='bottom' align='left'>16.22<hr></hr></td><td valign='bottom' align='left'>0.92 [0.77;1.11]<hr></hr></td><td valign='bottom' align='left'> <hr></hr></td></tr><tr><td valign='bottom' align='left'>Excessive daytime sleepiness<hr></hr></td><td valign='bottom' align='left'>Never/Rarely<hr></hr></td><td valign='bottom' align='left'>4,555<hr></hr></td><td valign='bottom' align='left'>84.52<hr></hr></td><td valign='bottom' align='left'>994<hr></hr></td><td valign='bottom' align='left'>76.05<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='left'>0.003<hr></hr></td></tr><tr><td align='left'> </td><td align='left'>Frequently/Often</td><td align='left'>834</td><td align='left'>15.48</td><td align='left'>313</td><td align='left'>23.95</td><td align='left'>1.23 [1.07;1.40]</td><td align='left'> </td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Adjusted for center study, gender and age; <sup>b</sup>university level; <sup>c</sup>history of cardiovascular disease (stroke or coronary heart disease; <sup>d</sup>number of insomnia complaints: difficulties in initiating sleep + difficulties in maintaining sleep + early morning awakening.</p></table-wrap-foot></table-wrap><p><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>Table 
<xref rid='T3' ref-type='table'>3</xref> shows the associations between hypnotic use at baseline and all-cause mortality over the 12-year follow-up.</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> After adjustment for age, gender, and study center, the risk of all-cause mortality increased significantly with the use of any hypnotic, the number of hypnotics, and alone for BZD (<italic>P</italic> &lt;0.01 for all comparisons, model 1).</s><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> When potential lifestyle and chronic disorder confounders were entered into the model (model 2), the HR were reduced and failed to be significant except for BZD (<italic>P</italic> = 0.05) and this was unchanged when further adjusting for sleep complaints (model 3).</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> When adjusting for anxiety and depressive symptomatology (model 4), the associations were not significant even for BZD (<italic>P</italic> = 0.22) and this was also the case for the complete multivariate model adjusted for all potential confounders (model 5).</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> BZD-like compounds, and miscellaneous medications intake were not associated with all-cause mortality even in the minimally adjusted model 1.</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> No significant interaction was found for mortality between hypnotic use and EDS, number of insomnia complaints, antidepressant use, chronic diseases, or being at risk for OSAS.</s></p><table-wrap position='float' id='T3'><label>Table 3</label><caption><p>Risks of death from all causes over 12-year according to hypnotic use</p></caption><table border='1' rules='groups' frame='hsides'><colgroup><col align='left'></col><col align='center'></col><col align='center'></col><col align='center'></col><col align='center'></col><col align='left'></col><col align='right'></col><col align='left'></col><col align='right'></col><col align='left'></col><col align='right'></col><col align='left'></col><col align='right'></col><col align='left'></col><col align='right'></col></colgroup><thead valign='top'><tr><th valign='bottom' align='left'> <hr></hr></th><th colspan='4' valign='bottom' align='center'><bold>All-cause death</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'> <hr></hr></th><th colspan='2' valign='bottom' align='center'> <hr></hr></th><th colspan='2' valign='bottom' align='center'> <hr></hr></th><th colspan='2' valign='bottom' align='center'> <hr></hr></th><th colspan='2' valign='bottom' align='center'> <hr></hr></th></tr><tr><th rowspan='2' valign='bottom' align='left'> <hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>No</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Yes</bold><hr></hr></th><th colspan='2' rowspan='2' valign='bottom' align='center'><bold>Model 1</bold><sup><bold>a</bold></sup><hr></hr></th><th colspan='2' rowspan='2' valign='bottom' align='center'><bold>Model 2</bold><sup><bold>b</bold></sup><hr></hr></th><th colspan='2' rowspan='2' valign='bottom' align='center'><bold>Model 3</bold><sup><bold>c</bold></sup><hr></hr></th><th colspan='2' rowspan='2' valign='bottom' align='center'><bold>Model 4</bold><sup><bold>d</bold></sup><hr></hr></th><th colspan='2' rowspan='2' valign='bottom' align='center'><bold>Model 5</bold><sup><bold>e</bold></sup><hr></hr></th></tr><tr><th colspan='2' valign='bottom' align='center'><bold>N = 5,389</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>N = 1,307</bold><hr></hr></th></tr><tr><th align='left'><bold>Variable</bold></th><th align='center'><bold>n</bold></th><th align='center'><bold>%</bold></th><th align='center'><bold>n</bold></th><th align='center'><bold>%</bold></th><th align='left'><bold>HR [95% CI]</bold></th><th align='right'><bold><italic>P</italic></bold></th><th align='left'><bold>HR [95% CI]</bold></th><th align='right'><bold><italic>P</italic></bold></th><th align='left'><bold>HR [95% CI]</bold></th><th align='right'><bold><italic>P</italic></bold></th><th align='left'><bold>HR [95% CI]</bold></th><th align='right'><bold><italic>P</italic></bold></th><th align='left'><bold>HR [95% CI]</bold></th><th align='right'><bold><italic>P</italic></bold></th></tr></thead><tbody valign='top'><tr><td colspan='15' valign='bottom' align='left'>Hypnotic use<hr></hr></td></tr><tr><td valign='bottom' align='left'> No<hr></hr></td><td valign='bottom' align='center'>4,261<hr></hr></td><td valign='bottom' align='center'>79.07<hr></hr></td><td valign='bottom' align='center'>981<hr></hr></td><td valign='bottom' align='center'>75.06<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.007<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.16<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.12<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.50<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.43<hr></hr></td></tr><tr><td valign='bottom' align='left'> Yes<hr></hr></td><td valign='bottom' align='center'>1,128<hr></hr></td><td valign='bottom' align='center'>20.93<hr></hr></td><td valign='bottom' align='center'>326<hr></hr></td><td valign='bottom' align='center'>24.94<hr></hr></td><td valign='bottom' align='left'>1.19 [1.05;1.36]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.10 [0.96;1.25]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.12 [0.97;1.29]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.05 [0.92;1.20]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.06 [0.92;1.23]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td></tr><tr><td colspan='15' valign='bottom' align='left'>Number of hypnotics<hr></hr></td></tr><tr><td valign='bottom' align='left'> 0<hr></hr></td><td valign='bottom' align='center'>4,261<hr></hr></td><td valign='bottom' align='center'>79.07<hr></hr></td><td valign='bottom' align='center'>981<hr></hr></td><td valign='bottom' align='center'>75.06<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.003<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.13<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.13<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.44<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.47<hr></hr></td></tr><tr><td valign='bottom' align='left'> 1<hr></hr></td><td valign='bottom' align='center'>970<hr></hr></td><td valign='bottom' align='center'>18.00<hr></hr></td><td valign='bottom' align='center'>272<hr></hr></td><td valign='bottom' align='center'>20.81<hr></hr></td><td valign='bottom' align='left'>1.14 [0.99;1.31]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.06 [0.93;1.22]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.09 [0.94;1.26]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.02 [0.89;1.18]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.04 [0.89;1.21]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> ≥2<hr></hr></td><td valign='bottom' align='center'>158<hr></hr></td><td valign='bottom' align='center'>2.93<hr></hr></td><td valign='bottom' align='center'>54<hr></hr></td><td valign='bottom' align='center'>4.13<hr></hr></td><td valign='bottom' align='left'>1.53 [1.16;2.01]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.32 [1.00;1.74]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.33 [0.98;1.81]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.20 [0.90;1.60]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.21 [0.88;1.65]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td></tr><tr><td colspan='15' valign='bottom' align='left'>BZD<hr></hr></td></tr><tr><td valign='bottom' align='left'> No<hr></hr></td><td valign='bottom' align='center'>4,557<hr></hr></td><td valign='bottom' align='center'>84.56<hr></hr></td><td valign='bottom' align='center'>1069<hr></hr></td><td valign='bottom' align='center'>81.79<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.003<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.05<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.05<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.22<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.21<hr></hr></td></tr><tr><td valign='bottom' align='left'> Yes<hr></hr></td><td valign='bottom' align='center'>832<hr></hr></td><td valign='bottom' align='center'>15.44<hr></hr></td><td valign='bottom' align='center'>238<hr></hr></td><td valign='bottom' align='center'>18.21<hr></hr></td><td valign='bottom' align='left'>1.24 [1.08;1.44]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.15 [1.00;1.33]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.17 [1.00;1.37]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.10 [0.95;1.28]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>1.11 [0.94;1.30]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td></tr><tr><td colspan='15' valign='bottom' align='left'>BZD-like compounds<hr></hr></td></tr><tr><td valign='bottom' align='left'> No<hr></hr></td><td valign='bottom' align='center'>5,135<hr></hr></td><td valign='bottom' align='center'>95.29<hr></hr></td><td valign='bottom' align='center'>1240<hr></hr></td><td valign='bottom' align='center'>94.87<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.93<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.56<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.76<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.40<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.55<hr></hr></td></tr><tr><td valign='bottom' align='left'> Yes<hr></hr></td><td valign='bottom' align='center'>254<hr></hr></td><td valign='bottom' align='center'>4.71<hr></hr></td><td valign='bottom' align='center'>67<hr></hr></td><td valign='bottom' align='center'>5.13<hr></hr></td><td valign='bottom' align='left'>1.01 [0.79;1.29]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>0.93 [0.72;1.19]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>0.96 [0.74;1.25]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>0.90 [0.70;1.15]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td><td valign='bottom' align='left'>0.92 [0.71;1.20]<hr></hr></td><td valign='bottom' align='right'> <hr></hr></td></tr><tr><td colspan='15' valign='bottom' align='left'>Miscellaneous medications<hr></hr></td></tr><tr><td valign='bottom' align='left'> No<hr></hr></td><td valign='bottom' align='center'>5,241<hr></hr></td><td valign='bottom' align='center'>97.25<hr></hr></td><td valign='bottom' align='center'>1251<hr></hr></td><td valign='bottom' align='center'>95.72<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.15<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.30<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.32<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.49<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='right'>0.49<hr></hr></td></tr><tr><td align='left'> Yes</td><td align='center'>148</td><td align='center'>2.75</td><td align='center'>56</td><td align='center'>4.28</td><td align='left'>1.22 [0.93;1.60]</td><td align='right'> </td><td align='left'>1.15 [0.88;1.51]</td><td align='right'> </td><td align='left'>1.16 [0.87;1.55]</td><td align='right'> </td><td align='left'>1.10 [0.84;1.45]</td><td align='right'> </td><td align='left'>1.11 [0.83;1.48]</td><td align='right'> </td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Adjusted for age, study center, and gender; <sup>b</sup>adjusted for age, study center, gender, level of education, confinement, alcohol intake, smoking status, history of cardio and cerebrovascular disease, respiratory disease, Mini Mental State Examination score, body mass index, hypertension, and diabetes mellitus; <sup>c</sup>adjusted for all the covariates in model 2, plus excessive daytime sleepiness and number of insomnia complaints; <sup>d</sup>adjusted for all the covariates in model 2, plus depressive symptoms, antidepressant use and Spielberger trait anxiety score; <sup>e</sup>adjusted for all the covariates in model 3 plus depressive symptoms, antidepressants use and Spielberger trait anxiety score. BZD, benzodiazepines; CI, confidence interval; HR, hazard ratios.</p></table-wrap-foot></table-wrap><p><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1>The relationship between hypnotic intake and the risk of mortality remained unchanged after exclusion of the participants who died during the first two years of follow-up (n = 134), the follow-up rate at two years being 88%.</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> With regard to specific causes of death, the use of hypnotics and BZD as well as number of hypnotics were associated with a significantly increased risk of CVD-related death in model 1, but not in the complete multivariate model adjusted for all potential confounders (Table 
<xref rid='T4' ref-type='table'>4</xref>).</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> There was no significant association between hypnotics and cancer-related death regardless of covariates, even in the minimally-adjusted model 1 (<italic>P</italic> = 0.38).</s></p><table-wrap position='float' id='T4'><label>Table 4</label><caption><p>Risks of cardiovascular disease and cancer as causes of death over 12 years according hypnotic use</p></caption><table border='1' rules='groups' frame='hsides'><colgroup><col align='left'></col><col align='center'></col><col align='center'></col><col align='center'></col><col align='center'></col><col align='left'></col><col align='center'></col><col align='left'></col><col align='center'></col><col align='left'></col><col align='center'></col><col align='left'></col><col align='center'></col><col align='left'></col><col align='center'></col><col align='left'></col><col align='center'></col></colgroup><thead valign='top'><tr><th valign='bottom' align='left'> <hr></hr></th><th colspan='8' valign='bottom' align='center'><bold>Cardiovascular disease deaths</bold><hr></hr></th><th colspan='8' valign='bottom' align='center'><bold>Cancer deaths</bold><hr></hr></th></tr><tr><th valign='bottom' align='left'> <hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>No n = 6,311</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Yes N = 385</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Model 1</bold><sup><bold>a</bold></sup><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Model 2</bold><sup><bold>b</bold></sup><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>No n = 6,174</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Yes N = 522</bold><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Model 1</bold><sup><bold>a</bold></sup><hr></hr></th><th colspan='2' valign='bottom' align='center'><bold>Model 2</bold><sup><bold>b</bold></sup><hr></hr></th></tr><tr><th align='left'><bold>Variable</bold></th><th align='center'><bold>n</bold></th><th align='center'><bold>%</bold></th><th align='center'><bold>n</bold></th><th align='center'><bold>%</bold></th><th align='center'><bold>HR [95% CI]</bold></th><th align='center'><bold><italic>P</italic></bold></th><th align='center'><bold>HR [95% CI]</bold></th><th align='center'><bold><italic>P</italic></bold></th><th align='center'><bold>n</bold></th><th align='center'><bold>%</bold></th><th align='center'><bold>n</bold></th><th align='center'><bold>%</bold></th><th align='center'><bold>HR [95% CI]</bold></th><th align='center'><bold><italic>P</italic></bold></th><th align='center'><bold>HR [95% CI]</bold></th><th align='center'><bold><italic>P</italic></bold></th></tr></thead><tbody valign='top'><tr><td colspan='17' valign='bottom' align='left'>Hypnotic use<hr></hr></td></tr><tr><td valign='bottom' align='left'> No<hr></hr></td><td valign='bottom' align='center'>4,962<hr></hr></td><td valign='bottom' align='center'>78.62<hr></hr></td><td valign='bottom' align='center'>280<hr></hr></td><td valign='bottom' align='center'>72.73<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.02<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.56<hr></hr></td><td valign='bottom' align='left'>4,818<hr></hr></td><td valign='bottom' align='center'>78.04<hr></hr></td><td valign='bottom' align='left'>424<hr></hr></td><td valign='bottom' align='center'>81.23<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.38<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.73<hr></hr></td></tr><tr><td valign='bottom' align='left'> Yes<hr></hr></td><td valign='bottom' align='center'>1,349<hr></hr></td><td valign='bottom' align='center'>21.38<hr></hr></td><td valign='bottom' align='center'>105<hr></hr></td><td valign='bottom' align='center'>27.27<hr></hr></td><td valign='bottom' align='left'>1.32 [1.04;1.66]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>0.92 [0.71;1.20]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>1,356<hr></hr></td><td valign='bottom' align='center'>21.96<hr></hr></td><td valign='bottom' align='left'>98<hr></hr></td><td valign='bottom' align='center'>18.77<hr></hr></td><td valign='bottom' align='left'>0.90 [0.72;1.13]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>0.96 [0.74;1.23]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td></tr><tr><td colspan='17' valign='bottom' align='left'>Number of hypnotics<hr></hr></td></tr><tr><td valign='bottom' align='left'> 0<hr></hr></td><td valign='bottom' align='center'>4,962<hr></hr></td><td valign='bottom' align='center'>78.62<hr></hr></td><td valign='bottom' align='center'>280<hr></hr></td><td valign='bottom' align='center'>72.73<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.03<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.78<hr></hr></td><td valign='bottom' align='left'>4,818<hr></hr></td><td valign='bottom' align='center'>78.04<hr></hr></td><td valign='bottom' align='left'>424<hr></hr></td><td valign='bottom' align='center'>81.23<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.67<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.94<hr></hr></td></tr><tr><td valign='bottom' align='left'> 1<hr></hr></td><td valign='bottom' align='center'>1,154<hr></hr></td><td valign='bottom' align='center'>18.29<hr></hr></td><td valign='bottom' align='center'>88<hr></hr></td><td valign='bottom' align='center'>22.86<hr></hr></td><td valign='bottom' align='left'>1.26 [0.99;1.61]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>0.94 [0.72;1.23]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>1,157<hr></hr></td><td valign='bottom' align='center'>18.74<hr></hr></td><td valign='bottom' align='left'>85<hr></hr></td><td valign='bottom' align='center'>16.28<hr></hr></td><td valign='bottom' align='left'>0.91 [0.72;1.15]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>0.96 [0.74;1.25]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td></tr><tr><td valign='bottom' align='left'> ≥2<hr></hr></td><td valign='bottom' align='center'>195<hr></hr></td><td valign='bottom' align='center'>3.09<hr></hr></td><td valign='bottom' align='center'>17<hr></hr></td><td valign='bottom' align='center'>4.42<hr></hr></td><td valign='bottom' align='left'>1.69 [1.03;2.76]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>0.83 [0.45;1.52]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>199<hr></hr></td><td valign='bottom' align='center'>3.22<hr></hr></td><td valign='bottom' align='left'>13<hr></hr></td><td valign='bottom' align='center'>2.49<hr></hr></td><td valign='bottom' align='left'>0.89 [0.51;1.54]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>0.93 [0.50;1.72]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td></tr><tr><td colspan='17' valign='bottom' align='left'>BZD<hr></hr></td></tr><tr><td valign='bottom' align='left'> No<hr></hr></td><td valign='bottom' align='center'>5,321<hr></hr></td><td valign='bottom' align='center'>84.31<hr></hr></td><td valign='bottom' align='center'>305<hr></hr></td><td valign='bottom' align='center'>79.22<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.004<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.60<hr></hr></td><td valign='bottom' align='left'>5,170<hr></hr></td><td valign='bottom' align='center'>83.74<hr></hr></td><td valign='bottom' align='left'>456<hr></hr></td><td valign='bottom' align='center'>87.36<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.27<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.42<hr></hr></td></tr><tr><td valign='bottom' align='left'> Yes<hr></hr></td><td valign='bottom' align='center'>990<hr></hr></td><td valign='bottom' align='center'>15.69<hr></hr></td><td valign='bottom' align='center'>80<hr></hr></td><td valign='bottom' align='center'>20.78<hr></hr></td><td valign='bottom' align='left'>1.45 [1.13;1.87]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>1.08 [0.81;1.43]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>1,004<hr></hr></td><td valign='bottom' align='center'>16.26<hr></hr></td><td valign='bottom' align='left'>66<hr></hr></td><td valign='bottom' align='center'>12.64<hr></hr></td><td valign='bottom' align='left'>0.86 [0.66;1.12]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>0.89 [0.66;1.19]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td></tr><tr><td colspan='17' valign='bottom' align='left'>BZD-like compounds<hr></hr></td></tr><tr><td valign='bottom' align='left'> No<hr></hr></td><td valign='bottom' align='center'>6,008<hr></hr></td><td valign='bottom' align='center'>95.20<hr></hr></td><td valign='bottom' align='center'>367<hr></hr></td><td valign='bottom' align='center'>95.32<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.65<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.12<hr></hr></td><td valign='bottom' align='left'>5,879<hr></hr></td><td valign='bottom' align='center'>95.22<hr></hr></td><td valign='bottom' align='left'>496<hr></hr></td><td valign='bottom' align='center'>95.02<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.78<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.44<hr></hr></td></tr><tr><td valign='bottom' align='left'> Yes<hr></hr></td><td valign='bottom' align='center'>303<hr></hr></td><td valign='bottom' align='center'>4.80<hr></hr></td><td valign='bottom' align='center'>18<hr></hr></td><td valign='bottom' align='center'>4.68<hr></hr></td><td valign='bottom' align='left'>0.90 [0.56;1.44]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>0.67 [0.40;1.11]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>295<hr></hr></td><td valign='bottom' align='center'>4.78<hr></hr></td><td valign='bottom' align='left'>26<hr></hr></td><td valign='bottom' align='center'>4.98<hr></hr></td><td valign='bottom' align='left'>1.06 [0.71;1.57]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td><td valign='bottom' align='left'>1.18 [0.77;1.82]<hr></hr></td><td valign='bottom' align='center'> <hr></hr></td></tr><tr><td colspan='17' valign='bottom' align='left'>Miscellaneous medications<hr></hr></td></tr><tr><td valign='bottom' align='left'> No<hr></hr></td><td valign='bottom' align='center'>6,123<hr></hr></td><td valign='bottom' align='center'>97.02<hr></hr></td><td valign='bottom' align='center'>369<hr></hr></td><td valign='bottom' align='center'>95.84<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.64<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.43<hr></hr></td><td valign='bottom' align='left'>5,986<hr></hr></td><td valign='bottom' align='center'>96.95<hr></hr></td><td valign='bottom' align='left'>506<hr></hr></td><td valign='bottom' align='center'>96.93<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.88<hr></hr></td><td valign='bottom' align='left'>1<hr></hr></td><td valign='bottom' align='center'>0.95<hr></hr></td></tr><tr><td align='left'> Yes</td><td align='center'>188</td><td align='center'>2.98</td><td align='center'>16</td><td align='center'>4.16</td><td align='left'>1.13 [0.68;1.87]</td><td align='center'> </td><td align='left'>0.80 [0.45;1.41]</td><td align='center'> </td><td align='left'>188</td><td align='center'>3.05</td><td align='left'>16</td><td align='center'>3.07</td><td align='left'>0.96 [0.58;1.59]</td><td align='center'> </td><td align='left'>1.02 [0.59;1.74]</td><td align='center'> </td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Adjusted for age, study center, and gender; <sup>b</sup>adjusted for all covariates in model 1 plus high level of education, confinement, alcohol intake, smoking status, history of cardio-cerebrovascular disease, respiratory disease, Mini Mental State Examination score, body mass index, hypertension and diabetes mellitus, depressive symptoms, antidepressants use, Spielberger trait anxiety score, excessive daytime sleepiness, and number of insomnia complaints. BZD, benzodiazepines; CI, confidence interval; HR, hazard ratios.</p></table-wrap-foot></table-wrap></sec><sec><title>Duration of hypnotic use and mortality</title><p><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Sensitivity analyses were performed to examine the relationship between persistent use of hypnotics during the initial 4 years and all-cause mortality.</s><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> A total of 3,496 participants (65.9%) did not report hypnotic use at baseline or at follow-up examination, 773 (14.5%) reported use both at baseline and at the first two follow-ups (persistent users) and 1,040 (19.6%) were taking hypnotics at one of two time points (intermittent users).</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> The risk of mortality for the next 8 years was not significantly associated with the persistent use of hypnotics (when compared with non-users, HR = 1.03, 95% CI = 0.84, 1.28 for intermittent users; HR = 1.11, 95% CI = 0.88, 1.39 for persistent users; multivariate model 5).</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Res1' type='Res'></CoreSc1> Similar results were obtained when the analyses focused on persistent BZD users in comparison to non persistent BZD users or non BZD users.</s></p><p><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>We also examined the impact of past hypnotic intake duration and compared participants who were not taking sleep medication at baseline with those having previously reported taking sleep medications for less than 5 years, between 5 and 10 years, between 10 and 20 years, and for more than 20 years.</s><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> No significant association was observed between duration of hypnotic intake and all-cause mortality, the global <italic>P</italic>-value ranging from 0.18 (model 1) to 0.76 (model 5) (data not shown).</s></p></sec></sec><sec sec-type='discussion'><title>Discussion</title><p><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>This study examined associations between hypnotic intake and risk of excess mortality (all-causes and specific causes) over a 12-year period in a large elderly cohort, taking into account a wide range of potential confounding factors.</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> As in several previous studies we observed significant associations between hypnotic use, notably BZDs, and mortality; however, these associations became non-significant after adjustment for all potential confounding factors, notably psychiatric disorder.</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> These findings persisted even after taking into account up to 20 years duration of past hypnotic intake or persistent versus intermittent use.</s></p><p><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Previous studies have been inconsistent, with some studies observing significant relationships between hypnotic prescriptions and mortality
[<xref rid='B16' ref-type='bibr'>16</xref>,<xref rid='B20' ref-type='bibr'>20</xref>-<xref rid='B25' ref-type='bibr'>25</xref>,<xref rid='B37' ref-type='bibr'>37</xref>] and others not
[<xref rid='B16' ref-type='bibr'>16</xref>-<xref rid='B19' ref-type='bibr'>19</xref>].</s><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Our findings suggest that these differences are probably largely due to failure to take into account confounding associations, notably common affective symptoms and sleep complaints, although other factors such as study design, participant age, and class of hypnotics probably also influence study outcome.</s></p><p><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Insomnia symptoms often lead to the use of hypnotics, a condition frequently associated with EDS, anxiety, and mood disorders.</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Depression and anxiety are also risk factors for mortality
[<xref rid='B14' ref-type='bibr'>14</xref>,<xref rid='B15' ref-type='bibr'>15</xref>].</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Depressive symptomatology and insomnia are both common in the elderly and in France there are no official guidelines for management, so antidepressants are often used to treat sleep disorder and hypnotics to treat depression, especially where sleep disturbance is one of the presenting symptoms
[<xref rid='B2' ref-type='bibr'>2</xref>].</s><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> EDS is also of multifactorial origin, and commonly associated with depression
[<xref rid='B7' ref-type='bibr'>7</xref>], cognitive decline
[<xref rid='B38' ref-type='bibr'>38</xref>], physical illness (particularly CVD), and mortality in older adults
[<xref rid='B5' ref-type='bibr'>5</xref>,<xref rid='B6' ref-type='bibr'>6</xref>,<xref rid='B13' ref-type='bibr'>13</xref>].</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Thus, all these conditions may increase the risk of mortality in elderly patients through pathways independently of hypnotics.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, few previous studies have controlled for psychological status
[<xref rid='B17' ref-type='bibr'>17</xref>,<xref rid='B18' ref-type='bibr'>18</xref>,<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B23' ref-type='bibr'>23</xref>] and in studies where depressive symptoms have been considered, antidepressant use has not been necessarily taken into account.</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This is important because antidepressant use may relieve depressive symptomatology, but the underlying biological risk factors associated with increased mortality may still be operating.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> No previous studies have controlled for anxiety or simultaneously for insomnia and EDS symptoms as potential independent confounding factors.</s><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> To our knowledge, our study is the first one controlling for such a large range of potential confounding factors, especially the underlying diseases associated with hypnotic use, such as anxiety and depressive symptomatology and antidepressant use, as well as EDS and insomnia complaints.</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Our finding that psychiatric disorder could be a principal determinant driving the association between hypnotics and mortality risk explains previous inconsistencies.</s></p><p><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Chronic use of hypnotic drugs, particularly BZD, may be associated with the risk of addiction and insomnia-rebound after withdrawal, psychomotor impairment and cognitive problems, OSAS, EDS, and car accidents
[<xref rid='B12' ref-type='bibr'>12</xref>,<xref rid='B39' ref-type='bibr'>39</xref>,<xref rid='B40' ref-type='bibr'>40</xref>].</s><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In our sample, only one participant died from a car accident, and this person did not use hypnotics.</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> We did not find any interaction between individuals clinically at risk for OSAS, hypnotics intake, and mortality, suggesting that if hypnotics trigger or aggravate OSAS they do not impact on mortality risk.</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The use of BZD may also favor falls and hip fractures and thus increase the risk for disability and death especially in the elderly
[<xref rid='B41' ref-type='bibr'>41</xref>,<xref rid='B42' ref-type='bibr'>42</xref>].</s><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However some studies have suggested that nighttime sleep problems may also be significant risk factors for falls in the elderly, independently of hypnotic use
[<xref rid='B43' ref-type='bibr'>43</xref>-<xref rid='B45' ref-type='bibr'>45</xref>].</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Obs1' type='Obs'></CoreSc1> In our study, the associations between hypnotic use and all-causes or CVD-related death became non-significant after adjustment for health behavior and status variables, plus EDS and insomnia complaints.</s></p><p><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>An increased incidence risk for cancer was also reported in individuals using hypnotics in some studies
[<xref rid='B21' ref-type='bibr'>21</xref>,<xref rid='B22' ref-type='bibr'>22</xref>,<xref rid='B24' ref-type='bibr'>24</xref>], even in infrequent hypnotic users
[<xref rid='B22' ref-type='bibr'>22</xref>].</s><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Our study did not report any association between hypnotic use and cancer-related death.</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Again, differences in adjustment of underlying co-morbid conditions frequently associated with the chronic use of hypnotics appear to explain previous findings.</s></p><p><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>The present study has some limitations.</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Unfortunately, data related to hypnotic dose were not available.</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Bias could have been introduced by the low participation rate at baseline and the non-random exclusion of participants with missing data at baseline – these participants were older, were more commonly hypnotics users, and more often had psychiatric and other chronic disorders that may limit the generalizability of our findings.</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Although unlikely, the possibility of overadjusment can not be excluded: potential confounding variables should be intermediate variables in the causal pathway between hypnotics intake and mortality.</s><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Finally, the absence of significant association between the use of hypnotics and mortality (all-causes, and CVD) after adjustments for covariates should be interpreted with caution regarding the small number of events per predictor variable.</s></p><p><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Our prospective study based on a large community sample has several strengths, including the duration of the follow-up and adjustment for a wide range of possible confounding factors including sociodemographic and lifestyle factors, chronic disorders, and sleep complaints as well as depression and anxiety disorders that were found as key confounding factors in this study.</s><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Prescriptions and medications themselves were checked by the interviewer and the causes of death were established by an independent committee.</s><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Finally, excluding participants who died during the first two years of follow-up did not modify the main results, suggesting a modest confounding effect of severe undiagnosed conditions in relation to hypnotic use and death.</s></p></sec><sec sec-type='conclusions'><title>Conclusions</title><p><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Our findings suggest that the use of hypnotics is not independently associated with an increased risk of mortality in the elderly, and that previous findings may be largely attributable to failure to take into account confounding variables, notably clinical co-morbidity, which is frequent at higher ages, particularly psychiatric disorders.</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Use of hypnotics might be a marker underlying more complex health issues.</s></p></sec><sec><title>Abbreviations</title><p>BMI: Body mass index; BZD: Benzodiazepines; CI: Confidence interval; CVD: Cardiovascular diseases; DIS: Difficulties in initiating sleep; DMS: Difficulties in maintaining sleep; EDS: Excessive daytime sleepiness; EMA: Early morning awakening; HR: Hazard ratios; ICD-10: International classification of diseases; OSAS: Obstructive sleep apnea syndrome.</p></sec><sec><title>Competing interests</title><p>The authors have nothing to disclose in relation to this paper. IJ, MLA, KP, JS and AB report no disclosures. KR has received honoraria from Novartis and Glaxo Smith-Kline; is on the scientific advisory boards for the Biomedical Research Centre, King’s College London, and the MRC Strategic Steering Committee (Longitudinal Health and Aging Research Unit); and serves on the editorial boards of the International Journal of Geriatric Psychiatry, Dementia, International Psychogeriatrics, Journal of Clinical and Experimental Gerontology, Psychogeriatrics, Neuronale, Neurologie-Psychiatrie-Gériatrie, and Gerontology. CB serves on advisory boards of the British Journal of Nutrition and Revue d’épidemiologie et de santé publique. YD has received speaker’s honoraria and support for travel to meetings from UCB Pharma, JAZZ and Bioprojet. YD participated in advisory boards of UCB Pharma, JAZZ and Bioprojet.</p></sec><sec><title>Authors’ contributions</title><p>IJ, MLA, and YD participated in the conception and design of the study. IJ conducted the analyses and wrote the first draft of the manuscript. IJ, MLA, AB, YD participated in the interpretation of the data. IJ, MLA, CB, KP, JS, AB, KR and YD contributed to the writing of the manuscript. MLA, CB, KP, JS, KR and YD participated in the acquisition of the data. All authors approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type='uri' xlink:href='http://www.biomedcentral.com/1741-7015/11/212/prepub'>http://www.biomedcentral.com/1741-7015/11/212/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>The 3C Study is conducted under a partnership agreement between Inserm, the Victor Segalen – Bordeaux II University and Sanofi-Synthélabo. The Fondation pour la Recherche Médicale funded the preparation and first phase of the study. The 3C-Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Agence Française de Sécurité Sanitaire des Produits de Santé, the Regional Governments of Aquitaine, Bourgogne and Languedoc-Roussillon and, the Fondation de France, the Ministry of Research-Inserm Programme “Cohorts and collection of biological material”. The Lille Génopôle received an unconditional grant from Eisai. Part of this project is financed by grants from the Agence Nationale de la Recherche and Fondation Plan Alzheimer. None of the sponsors had any further involvement in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.</p></sec><ref-list><ref id='B1'><mixed-citation publication-type='journal'><name><surname>Bloom</surname><given-names>HG</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Alessi</surname><given-names>CA</given-names></name><name><surname>Ancoli-Israel</surname><given-names>S</given-names></name><name><surname>Buysse</surname><given-names>DJ</given-names></name><name><surname>Kryger</surname><given-names>MH</given-names></name><name><surname>Phillips</surname><given-names>BA</given-names></name><name><surname>Thorpy</surname><given-names>MJ</given-names></name><name><surname>Vitiello</surname><given-names>MV</given-names></name><name><surname>Zee</surname><given-names>PC</given-names></name><article-title>Evidence-based recommendations for the assessment and management of sleep disorders in older persons</article-title><source>J Am Geriatr Soc</source><year>2009</year><volume>57</volume><fpage>761</fpage><lpage>789</lpage><pub-id pub-id-type='doi'>10.1111/j.1532-5415.2009.02220.x</pub-id><pub-id pub-id-type='pmid'>19484833</pub-id></mixed-citation></ref><ref id='B2'><mixed-citation publication-type='journal'><name><surname>Morin</surname><given-names>CM</given-names></name><name><surname>Benca</surname><given-names>R</given-names></name><article-title>Chronic insomnia</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>1129</fpage><lpage>1141</lpage><pub-id pub-id-type='doi'>10.1016/S0140-6736(11)60750-2</pub-id><pub-id pub-id-type='pmid'>22265700</pub-id></mixed-citation></ref><ref id='B3'><mixed-citation publication-type='journal'><name><surname>Morin</surname><given-names>CM</given-names></name><name><surname>LeBlanc</surname><given-names>M</given-names></name><name><surname>Daley</surname><given-names>M</given-names></name><name><surname>Gregoire</surname><given-names>JP</given-names></name><name><surname>Merette</surname><given-names>C</given-names></name><article-title>Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors</article-title><source>Sleep Med</source><year>2006</year><volume>7</volume><fpage>123</fpage><lpage>130</lpage><pub-id pub-id-type='doi'>10.1016/j.sleep.2005.08.008</pub-id><pub-id pub-id-type='pmid'>16459140</pub-id></mixed-citation></ref><ref id='B4'><mixed-citation publication-type='journal'><name><surname>Ohayon</surname><given-names>MM</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name><name><surname>Reynolds</surname><given-names>CF</given-names><suffix>3rd</suffix></name><article-title>Operational definitions and algorithms for excessive sleepiness in the general population: implications for DSM-5 nosology</article-title><source>Arch Gen Psychiatry</source><year>2012</year><volume>69</volume><fpage>71</fpage><lpage>79</lpage><pub-id pub-id-type='doi'>10.1001/archgenpsychiatry.2011.1240</pub-id><pub-id pub-id-type='pmid'>22213791</pub-id></mixed-citation></ref><ref id='B5'><mixed-citation publication-type='journal'><name><surname>Blachier</surname><given-names>M</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name><name><surname>Jaussent</surname><given-names>I</given-names></name><name><surname>Helmer</surname><given-names>C</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Jouven</surname><given-names>X</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Besset</surname><given-names>A</given-names></name><name><surname>Ducimetiere</surname><given-names>P</given-names></name><name><surname>Empana</surname><given-names>JP</given-names></name><article-title>Excessive daytime sleepiness and vascular events: the Three City Study</article-title><source>Ann Neurol</source><year>2012</year><volume>71</volume><fpage>661</fpage><lpage>667</lpage><pub-id pub-id-type='doi'>10.1002/ana.22656</pub-id><pub-id pub-id-type='pmid'>22271307</pub-id></mixed-citation></ref><ref id='B6'><mixed-citation publication-type='journal'><name><surname>Jaussent</surname><given-names>I</given-names></name><name><surname>Empana</surname><given-names>JP</given-names></name><name><surname>Ancelin</surname><given-names>ML</given-names></name><name><surname>Besset</surname><given-names>A</given-names></name><name><surname>Helmer</surname><given-names>C</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Bouyer</surname><given-names>J</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name><article-title>Insomnia, daytime sleepiness and cardio-cerebrovascular diseases in the elderly: a 6-year prospective study</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e56048</fpage><pub-id pub-id-type='doi'>10.1371/journal.pone.0056048</pub-id><pub-id pub-id-type='pmid'>23457496</pub-id></mixed-citation></ref><ref id='B7'><mixed-citation publication-type='journal'><name><surname>Jaussent</surname><given-names>I</given-names></name><name><surname>Bouyer</surname><given-names>J</given-names></name><name><surname>Ancelin</surname><given-names>ML</given-names></name><name><surname>Akbaraly</surname><given-names>T</given-names></name><name><surname>Peres</surname><given-names>K</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Besset</surname><given-names>A</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name><article-title>Insomnia and daytime sleepiness are risk factors for depressive symptoms in the elderly</article-title><source>Sleep</source><year>2011</year><volume>34</volume><fpage>1103</fpage><lpage>1110</lpage><pub-id pub-id-type='pmid'>21804672</pub-id></mixed-citation></ref><ref id='B8'><mixed-citation publication-type='journal'><name><surname>Mellinger</surname><given-names>GD</given-names></name><name><surname>Balter</surname><given-names>MB</given-names></name><name><surname>Uhlenhuth</surname><given-names>EH</given-names></name><article-title>Insomnia and its treatment. Prevalence and correlates</article-title><source>Arch Gen Psychiatry</source><year>1985</year><volume>42</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type='doi'>10.1001/archpsyc.1985.01790260019002</pub-id><pub-id pub-id-type='pmid'>2858188</pub-id></mixed-citation></ref><ref id='B9'><mixed-citation publication-type='journal'><name><surname>Ohayon</surname><given-names>MM</given-names></name><name><surname>Caulet</surname><given-names>M</given-names></name><article-title>Psychotropic medication and insomnia complaints in two epidemiological studies</article-title><source>Can J Psychiatry</source><year>1996</year><volume>41</volume><fpage>457</fpage><lpage>464</lpage><pub-id pub-id-type='pmid'>8884035</pub-id></mixed-citation></ref><ref id='B10'><mixed-citation publication-type='journal'><name><surname>Ohayon</surname><given-names>MM</given-names></name><name><surname>Caulet</surname><given-names>M</given-names></name><name><surname>Priest</surname><given-names>RG</given-names></name><name><surname>Guilleminault</surname><given-names>C</given-names></name><article-title>Psychotropic medication consumption patterns in the UK general population</article-title><source>J Clin Epidemiol</source><year>1998</year><volume>51</volume><fpage>273</fpage><lpage>283</lpage><pub-id pub-id-type='doi'>10.1016/S0895-4356(97)00238-2</pub-id><pub-id pub-id-type='pmid'>9495693</pub-id></mixed-citation></ref><ref id='B11'><mixed-citation publication-type='journal'><name><surname>Quera-Salva</surname><given-names>MA</given-names></name><name><surname>Orluc</surname><given-names>A</given-names></name><name><surname>Goldenberg</surname><given-names>F</given-names></name><name><surname>Guilleminault</surname><given-names>C</given-names></name><article-title>Insomnia and use of hypnotics: study of a French population</article-title><source>Sleep</source><year>1991</year><volume>14</volume><fpage>386</fpage><lpage>391</lpage><pub-id pub-id-type='pmid'>1759090</pub-id></mixed-citation></ref><ref id='B12'><mixed-citation publication-type='journal'><name><surname>Vermeeren</surname><given-names>A</given-names></name><article-title>Residual effects of hypnotics: epidemiology and clinical implications</article-title><source>CNS Drugs</source><year>2004</year><volume>18</volume><fpage>297</fpage><lpage>328</lpage><pub-id pub-id-type='doi'>10.2165/00023210-200418050-00003</pub-id><pub-id pub-id-type='pmid'>15089115</pub-id></mixed-citation></ref><ref id='B13'><mixed-citation publication-type='journal'><name><surname>Empana</surname><given-names>JP</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Gariepy</surname><given-names>J</given-names></name><name><surname>Jouven</surname><given-names>X</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Amouyel</surname><given-names>P</given-names></name><name><surname>Besset</surname><given-names>A</given-names></name><name><surname>Ducimetiere</surname><given-names>P</given-names></name><article-title>Excessive daytime sleepiness is an independent risk indicator for cardiovascular mortality in community-dwelling elderly: the three city study</article-title><source>Stroke</source><year>2009</year><volume>40</volume><fpage>1219</fpage><lpage>1224</lpage><pub-id pub-id-type='doi'>10.1161/STROKEAHA.108.530824</pub-id><pub-id pub-id-type='pmid'>19246707</pub-id></mixed-citation></ref><ref id='B14'><mixed-citation publication-type='other'><name><surname>Carrière</surname><given-names>I</given-names></name><name><surname>Ryan</surname><given-names>J</given-names></name><name><surname>Norton</surname><given-names>J</given-names></name><name><surname>Scali</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Ancelin</surname><given-names>M</given-names></name><article-title>Anxiety and risk of death in the elderly: the Esprit study</article-title><source>Br J Psychiatry</source><year>2013</year><comment>in press</comment></mixed-citation></ref><ref id='B15'><mixed-citation publication-type='journal'><name><surname>Ryan</surname><given-names>J</given-names></name><name><surname>Carriere</surname><given-names>I</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Toulemonde</surname><given-names>G</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Ancelin</surname><given-names>ML</given-names></name><article-title>Late-life depression and mortality: influence of gender and antidepressant use</article-title><source>Br J Psychiatry</source><year>2008</year><volume>192</volume><fpage>12</fpage><lpage>18</lpage><pub-id pub-id-type='doi'>10.1192/bjp.bp.107.039164</pub-id><pub-id pub-id-type='pmid'>18174502</pub-id></mixed-citation></ref><ref id='B16'><mixed-citation publication-type='journal'><name><surname>Kojima</surname><given-names>M</given-names></name><name><surname>Wakai</surname><given-names>K</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Tamakoshi</surname><given-names>A</given-names></name><name><surname>Aoki</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Horibe</surname><given-names>H</given-names></name><name><surname>Aoki</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>Y</given-names></name><article-title>Sleep patterns and total mortality: a 12-year follow-up study in Japan</article-title><source>J Epidemiol</source><year>2000</year><volume>10</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type='doi'>10.2188/jea.10.87</pub-id><pub-id pub-id-type='pmid'>10778032</pub-id></mixed-citation></ref><ref id='B17'><mixed-citation publication-type='journal'><name><surname>Phillips</surname><given-names>B</given-names></name><name><surname>Mannino</surname><given-names>DM</given-names></name><article-title>Does insomnia kill?</article-title><source>Sleep</source><year>2005</year><volume>28</volume><fpage>965</fpage><lpage>971</lpage><pub-id pub-id-type='pmid'>16218079</pub-id></mixed-citation></ref><ref id='B18'><mixed-citation publication-type='journal'><name><surname>Hays</surname><given-names>JC</given-names></name><name><surname>Blazer</surname><given-names>DG</given-names></name><name><surname>Foley</surname><given-names>DJ</given-names></name><article-title>Risk of napping: excessive daytime sleepiness and mortality in an older community population</article-title><source>J Am Geriatr Soc</source><year>1996</year><volume>44</volume><fpage>693</fpage><lpage>698</lpage><pub-id pub-id-type='pmid'>8642162</pub-id></mixed-citation></ref><ref id='B19'><mixed-citation publication-type='journal'><name><surname>Rumble</surname><given-names>R</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><article-title>Hypnotics, sleep, and mortality in elderly people</article-title><source>J Am Geriatr Soc</source><year>1992</year><volume>40</volume><fpage>787</fpage><lpage>791</lpage><pub-id pub-id-type='pmid'>1634722</pub-id></mixed-citation></ref><ref id='B20'><mixed-citation publication-type='journal'><name><surname>Hausken</surname><given-names>AM</given-names></name><name><surname>Skurtveit</surname><given-names>S</given-names></name><name><surname>Tverdal</surname><given-names>A</given-names></name><article-title>Use of anxiolytic or hypnotic drugs and total mortality in a general middle-aged population</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2007</year><volume>16</volume><fpage>913</fpage><lpage>918</lpage><pub-id pub-id-type='doi'>10.1002/pds.1417</pub-id><pub-id pub-id-type='pmid'>17486666</pub-id></mixed-citation></ref><ref id='B21'><mixed-citation publication-type='journal'><name><surname>Kripke</surname><given-names>DF</given-names></name><name><surname>Langer</surname><given-names>RD</given-names></name><name><surname>Kline</surname><given-names>LE</given-names></name><article-title>Hypnotics’ association with mortality or cancer: a matched cohort study</article-title><source>BMJ Open</source><year>2012</year><volume>2</volume><fpage>e000850</fpage><pub-id pub-id-type='doi'>10.1136/bmjopen-2012-000850</pub-id><pub-id pub-id-type='pmid'>22371848</pub-id></mixed-citation></ref><ref id='B22'><mixed-citation publication-type='journal'><name><surname>Mallon</surname><given-names>L</given-names></name><name><surname>Broman</surname><given-names>JE</given-names></name><name><surname>Hetta</surname><given-names>J</given-names></name><article-title>Is usage of hypnotics associated with mortality?</article-title><source>Sleep Med</source><year>2009</year><volume>10</volume><fpage>279</fpage><lpage>286</lpage><pub-id pub-id-type='doi'>10.1016/j.sleep.2008.12.004</pub-id><pub-id pub-id-type='pmid'>19269892</pub-id></mixed-citation></ref><ref id='B23'><mixed-citation publication-type='journal'><name><surname>Belleville</surname><given-names>G</given-names></name><article-title>Mortality hazard associated with anxiolytic and hypnotic drug use in the national population health survey</article-title><source>Can J Psychiatry</source><year>2010</year><volume>55</volume><fpage>558</fpage><lpage>567</lpage><pub-id pub-id-type='pmid'>20840803</pub-id></mixed-citation></ref><ref id='B24'><mixed-citation publication-type='journal'><name><surname>Kripke</surname><given-names>DF</given-names></name><name><surname>Garfinkel</surname><given-names>L</given-names></name><name><surname>Wingard</surname><given-names>DL</given-names></name><name><surname>Klauber</surname><given-names>MR</given-names></name><name><surname>Marler</surname><given-names>MR</given-names></name><article-title>Mortality associated with sleep duration and insomnia</article-title><source>Arch Gen Psychiatry</source><year>2002</year><volume>59</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type='doi'>10.1001/archpsyc.59.2.131</pub-id><pub-id pub-id-type='pmid'>11825133</pub-id></mixed-citation></ref><ref id='B25'><mixed-citation publication-type='journal'><name><surname>Kripke</surname><given-names>DF</given-names></name><name><surname>Klauber</surname><given-names>MR</given-names></name><name><surname>Wingard</surname><given-names>DL</given-names></name><name><surname>Fell</surname><given-names>RL</given-names></name><name><surname>Assmus</surname><given-names>JD</given-names></name><name><surname>Garfinkel</surname><given-names>L</given-names></name><article-title>Mortality hazard associated with prescription hypnotics</article-title><source>Biol Psychiatry</source><year>1998</year><volume>43</volume><fpage>687</fpage><lpage>693</lpage><pub-id pub-id-type='doi'>10.1016/S0006-3223(97)00292-8</pub-id><pub-id pub-id-type='pmid'>9583003</pub-id></mixed-citation></ref><ref id='B26'><mixed-citation publication-type='journal'><collab>3C Study Group</collab><article-title>Vascular factors and risk of dementia: design of the three-city study and baseline characteristics of the study population</article-title><source>Neuroepidemiol</source><year>2003</year><volume>22</volume><fpage>316</fpage><lpage>325</lpage></mixed-citation></ref><ref id='B27'><mixed-citation publication-type='journal'><name><surname>Alperovitch</surname><given-names>A</given-names></name><name><surname>Bertrand</surname><given-names>M</given-names></name><name><surname>Jougla</surname><given-names>E</given-names></name><name><surname>Vidal</surname><given-names>JS</given-names></name><name><surname>Ducimetiere</surname><given-names>P</given-names></name><name><surname>Helmer</surname><given-names>C</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Pavillon</surname><given-names>G</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><article-title>Do we really know the cause of death of the very old? Comparison between official mortality statistics and cohort study classification</article-title><source>Eur J Epidemiol</source><year>2009</year><volume>24</volume><fpage>669</fpage><lpage>675</lpage><pub-id pub-id-type='doi'>10.1007/s10654-009-9383-2</pub-id><pub-id pub-id-type='pmid'>19728117</pub-id></mixed-citation></ref><ref id='B28'><mixed-citation publication-type='book'><collab>World Health Organization</collab><source>International Statistical Classification of Diseases and Related Health Problems</source><year>1992</year><edition>10</edition><publisher-name>Geneva; Switzerland: WHO</publisher-name></mixed-citation></ref><ref id='B29'><mixed-citation publication-type='journal'><name><surname>Radloff</surname><given-names>LS</given-names></name><article-title>The CES-D Scale: a self-report depression scale for research in the general population</article-title><source>App Psychol Measure</source><year>1977</year><volume>1</volume><fpage>385</fpage><lpage>401</lpage><pub-id pub-id-type='doi'>10.1177/014662167700100306</pub-id></mixed-citation></ref><ref id='B30'><mixed-citation publication-type='book'><name><surname>Spielberger</surname><given-names>C</given-names></name><source>Manual for the State-Trait Anxiety Inventory (Form Y)</source><year>1983</year><publisher-name>Palo Alto, CA: Consulting Psychologists Press</publisher-name></mixed-citation></ref><ref id='B31'><mixed-citation publication-type='journal'><name><surname>Folstein</surname><given-names>MF</given-names></name><name><surname>Folstein</surname><given-names>SE</given-names></name><name><surname>McHugh</surname><given-names>PR</given-names></name><article-title>Mini-mental state. A practical method for grading the cognitive state of patients for the clinician</article-title><source>J Psychiatr Res</source><year>1975</year><volume>12</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type='doi'>10.1016/0022-3956(75)90026-6</pub-id><pub-id pub-id-type='pmid'>1202204</pub-id></mixed-citation></ref><ref id='B32'><mixed-citation publication-type='book'><collab>World Health Organization</collab><source>International Classification of Functioning, Disability and Health</source><year>2001</year><publisher-name>Geneva, Switzerland: WHO</publisher-name></mixed-citation></ref><ref id='B33'><mixed-citation publication-type='journal'><name><surname>Jaussent</surname><given-names>I</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name><name><surname>Ancelin</surname><given-names>ML</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Tavernier</surname><given-names>B</given-names></name><name><surname>Touchon</surname><given-names>J</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Besset</surname><given-names>A</given-names></name><article-title>Insomnia symptoms in older adults: associated factors and gender differences</article-title><source>Am J Geriatr Psychiatry</source><year>2011</year><volume>19</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type='doi'>10.1097/JGP.0b013e3181e049b6</pub-id><pub-id pub-id-type='pmid'>20808113</pub-id></mixed-citation></ref><ref id='B34'><mixed-citation publication-type='book'><collab>World Health Organization</collab><source>World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment</source><year>2000</year><publisher-name>Oslo, Norway: WHO</publisher-name></mixed-citation></ref><ref id='B35'><mixed-citation publication-type='journal'><name><surname>Commenges</surname><given-names>D</given-names></name><name><surname>Letenneur</surname><given-names>L</given-names></name><name><surname>Joly</surname><given-names>P</given-names></name><name><surname>Alioum</surname><given-names>A</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><article-title>Modelling age-specific risk: application to dementia</article-title><source>Stat Med</source><year>1998</year><volume>17</volume><fpage>1973</fpage><lpage>1988</lpage><pub-id pub-id-type='doi'>10.1002/(SICI)1097-0258(19980915)17:17&lt;1973::AID-SIM892&gt;3.0.CO;2-5</pub-id><pub-id pub-id-type='pmid'>9777690</pub-id></mixed-citation></ref><ref id='B36'><mixed-citation publication-type='journal'><name><surname>Thiebaut</surname><given-names>AC</given-names></name><name><surname>Benichou</surname><given-names>J</given-names></name><article-title>Choice of time-scale in Cox’s model analysis of epidemiologic cohort data: a simulation study</article-title><source>Stat Med</source><year>2004</year><volume>23</volume><fpage>3803</fpage><lpage>3820</lpage><pub-id pub-id-type='doi'>10.1002/sim.2098</pub-id><pub-id pub-id-type='pmid'>15580597</pub-id></mixed-citation></ref><ref id='B37'><mixed-citation publication-type='journal'><name><surname>Hublin</surname><given-names>C</given-names></name><name><surname>Partinen</surname><given-names>M</given-names></name><name><surname>Koskenvuo</surname><given-names>M</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><article-title>Sleep and mortality: a population-based 22-year follow-up study</article-title><source>Sleep</source><year>2007</year><volume>30</volume><fpage>1245</fpage><lpage>1253</lpage><pub-id pub-id-type='pmid'>17969458</pub-id></mixed-citation></ref><ref id='B38'><mixed-citation publication-type='journal'><name><surname>Jaussent</surname><given-names>I</given-names></name><name><surname>Bouyer</surname><given-names>J</given-names></name><name><surname>Ancelin</surname><given-names>ML</given-names></name><name><surname>Berr</surname><given-names>C</given-names></name><name><surname>Foubert-Samier</surname><given-names>A</given-names></name><name><surname>Ritchie</surname><given-names>K</given-names></name><name><surname>Ohayon</surname><given-names>MM</given-names></name><name><surname>Besset</surname><given-names>A</given-names></name><name><surname>Dauvilliers</surname><given-names>Y</given-names></name><article-title>Excessive sleepiness is predictive of cognitive decline in the elderly</article-title><source>Sleep</source><year>2012</year><volume>35</volume><fpage>1201</fpage><lpage>1207</lpage><pub-id pub-id-type='pmid'>22942498</pub-id></mixed-citation></ref><ref id='B39'><mixed-citation publication-type='journal'><name><surname>Billioti De Gage</surname><given-names>S</given-names></name><name><surname>Begaud</surname><given-names>B</given-names></name><name><surname>Bazin</surname><given-names>F</given-names></name><name><surname>Verdoux</surname><given-names>H</given-names></name><name><surname>Dartigues</surname><given-names>JF</given-names></name><name><surname>Peres</surname><given-names>K</given-names></name><name><surname>Kurth</surname><given-names>T</given-names></name><name><surname>Pariente</surname><given-names>A</given-names></name><article-title>Benzodiazepine use and risk of dementia: prospective population based study</article-title><source>BMJ</source><year>2012</year><volume>345</volume><fpage>e6231</fpage><pub-id pub-id-type='doi'>10.1136/bmj.e6231</pub-id><pub-id pub-id-type='pmid'>23045258</pub-id></mixed-citation></ref><ref id='B40'><mixed-citation publication-type='journal'><name><surname>Guilleminault</surname><given-names>C</given-names></name><article-title>Benzodiazepines, breathing, and sleep</article-title><source>Am J Med</source><year>1990</year><volume>88</volume><fpage>25S</fpage><lpage>28S</lpage><pub-id pub-id-type='pmid'>1968716</pub-id></mixed-citation></ref><ref id='B41'><mixed-citation publication-type='journal'><name><surname>MacDonald</surname><given-names>JB</given-names></name><name><surname>MacDonald</surname><given-names>ET</given-names></name><article-title>Nocturnal femoral fracture and continuing widespread use of barbiturate hypnotics</article-title><source>Br Med J</source><year>1977</year><volume>2</volume><fpage>483</fpage><lpage>485</lpage><pub-id pub-id-type='doi'>10.1136/bmj.2.6085.483</pub-id><pub-id pub-id-type='pmid'>890361</pub-id></mixed-citation></ref><ref id='B42'><mixed-citation publication-type='journal'><name><surname>Ray</surname><given-names>WA</given-names></name><name><surname>Griffin</surname><given-names>MR</given-names></name><name><surname>Schaffner</surname><given-names>W</given-names></name><name><surname>Baugh</surname><given-names>DK</given-names></name><name><surname>Melton</surname><given-names>LJ</given-names><suffix>3rd</suffix></name><article-title>Psychotropic drug use and the risk of hip fracture</article-title><source>N Engl J Med</source><year>1987</year><volume>316</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type='doi'>10.1056/NEJM198702123160702</pub-id><pub-id pub-id-type='pmid'>2880292</pub-id></mixed-citation></ref><ref id='B43'><mixed-citation publication-type='journal'><name><surname>Avidan</surname><given-names>AY</given-names></name><name><surname>Fries</surname><given-names>BE</given-names></name><name><surname>James</surname><given-names>ML</given-names></name><name><surname>Szafara</surname><given-names>KL</given-names></name><name><surname>Wright</surname><given-names>GT</given-names></name><name><surname>Chervin</surname><given-names>RD</given-names></name><article-title>Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes</article-title><source>J Am Geriatr Soc</source><year>2005</year><volume>53</volume><fpage>955</fpage><lpage>962</lpage><pub-id pub-id-type='doi'>10.1111/j.1532-5415.2005.53304.x</pub-id><pub-id pub-id-type='pmid'>15935017</pub-id></mixed-citation></ref><ref id='B44'><mixed-citation publication-type='journal'><name><surname>Brassington</surname><given-names>GS</given-names></name><name><surname>King</surname><given-names>AC</given-names></name><name><surname>Bliwise</surname><given-names>DL</given-names></name><article-title>Sleep problems as a risk factor for falls in a sample of community-dwelling adults aged 64–99 years</article-title><source>J Am Geriatr Soc</source><year>2000</year><volume>48</volume><fpage>1234</fpage><lpage>1240</lpage><pub-id pub-id-type='pmid'>11037010</pub-id></mixed-citation></ref><ref id='B45'><mixed-citation publication-type='journal'><name><surname>Stone</surname><given-names>KL</given-names></name><name><surname>Ancoli-Israel</surname><given-names>S</given-names></name><name><surname>Blackwell</surname><given-names>T</given-names></name><name><surname>Ensrud</surname><given-names>KE</given-names></name><name><surname>Cauley</surname><given-names>JA</given-names></name><name><surname>Redline</surname><given-names>S</given-names></name><name><surname>Hillier</surname><given-names>TA</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Claman</surname><given-names>D</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name><article-title>Actigraphy-measured sleep characteristics and risk of falls in older women</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><fpage>1768</fpage><lpage>1775</lpage><pub-id pub-id-type='doi'>10.1001/archinte.168.16.1768</pub-id><pub-id pub-id-type='pmid'>18779464</pub-id></mixed-citation></ref></ref-list></back></article></PAPER>